<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oral toxicity associated with systemic anticancer therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oral toxicity associated with systemic anticancer therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Oral toxicity associated with systemic anticancer therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nathaniel S Treister, DMD, DMSc, DABOM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Oral complications resulting from systemic anticancer therapy include mucositis, saliva changes, taste alterations, infection, and gingival bleeding. [<a href="#rid1">1,2</a>]. All of these complications can cause pain and/or impair nutrition.</p><p>Disruptions in the function and/or integrity of the mucosal lining of the gastrointestinal tract are a particularly important problem in patients receiving chemotherapy. Mucositis, which reflects a short-term, self-limited adverse effect of treatment, can affect the entire alimentary tract. The range of symptoms includes oral ulcerations, dysphagia and odynophagia, esophagitis, gastritis, diarrhea, and malabsorption.</p><p>Chemotherapy-associated acute oral toxicity will be reviewed here. Oral mucositis in the setting of high-dose chemotherapy and hematopoietic cell transplantation is discussed in detail elsewhere, as are radiation-induced oral mucositis, osteonecrosis of the jaw related to use of antiresorptive therapy and angiogenesis inhibitors in patients with advanced cancer, and late oral toxicities in cancer survivors. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer"</a> and  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Mucositis'</a> and  <a class="medical medical_review" href="/d/html/16346.html" rel="external">"Oral health in cancer survivors"</a> and  <a class="medical medical_review" href="/d/html/96863.html" rel="external">"Medication-related osteonecrosis of the jaw in patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MUCOSITIS</span><span class="headingEndMark"> — </span>Oral mucositis affects on average 20 to 40 percent of patients receiving conventional-dose cytotoxic chemotherapy [<a href="#rid3">3-5</a>]. The frequency is higher (up to 80 percent) in those undergoing hematopoietic cell transplantation (HCT), particularly myeloablative allogeneic HCT, and in those who are prepared with radiation-containing regimens and with the use of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for graft-versus-host disease prophylaxis. An exception is in the setting of reduced-intensity or non-myeloablative allogeneic HCT, where mucositis is rare. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Pathobiology</span><span class="headingEndMark"> — </span>The pathobiology underlying damage to the oral mucosal barrier is complex, and a series of stages has been described in patients treated with conventional cytotoxic chemotherapy agents, summarized as follows [<a href="#rid3">3-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Initiation – Chemotherapy and radiation therapy damage both DNA and non-DNA targets, both as a direct effect and mediated through reactive oxygen species.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upregulation and generation of messenger signals – The initial injury activates the transcription factor nuclear factor-kappa B, leading to the production of a variety of biologically active proteins, including proinflammatory cytokines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signaling and amplification – As proinflammatory cytokines accumulate, they damage surrounding tissues directly, and the effect is amplified via feedback loops. This phase precedes the development of overt clinical mucositis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ulceration and inflammation – Loss of mucosal integrity results in clinically painful lesions and allows secondary bacterial colonization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Healing – Mucositis generally is self-limited, and healing begins once the tissue insult is withdrawn.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Etiology and risk factors</span><span class="headingEndMark"> — </span>Multiple factors influence the extent and severity of mucositis, including the specific drug, dose, route and frequency of administration, individual patient tolerance, genetic variants in drug metabolizing pathways, immune signaling and cell injury/repair mechanisms, and possibly smoking history [<a href="#rid6">6</a>]. The most robust data support dosimetric parameters as key predictors of mucositis risk. A comprehensive list of cancer treatment drugs with the potential to cause oral mucositis is provided in the following table  (<a class="graphic graphic_table graphicRef68013" href="/d/graphic/68013.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H341905718"><span class="h3">Specific anticancer agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic chemotherapy agents</strong> – In general, chemotherapeutic agents that are DNA cell cycle specific (eg, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> [FU], and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>) are more stomatotoxic than those that are cell phase nonspecific (eg, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, anthracyclines) [<a href="#rid7">7</a>]. Certain drugs (eg, methotrexate, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>) may be secreted into the saliva [<a href="#rid8">8-10</a>], and it is postulated that this might increase the potential for stomatotoxicity.</p><p></p><p class="bulletIndent1">The conventional cytotoxic drugs used to treat cancer that are most commonly associated with mucositis are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">Etoposide</a> (high-dose)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">Melphalan</a> (high-dose)</p><p class="bulletIndent2"><span class="glyph">•</span>FU (bolus administration schedules)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecularly targeted agents</strong> – The range of reported rates of stomatitis in patients receiving molecularly targeted agents is broad, and depends on the class of agent:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oral mucositis is reported in 30 to 40 percent of patients receiving therapy with the molecularly targeted agents <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>, and <a class="drug drug_general" data-topicid="86690" href="/d/drug information/86690.html" rel="external">regorafenib</a> (which are orally active receptor tyrosine kinase inhibitors that target, among others, vascular endothelial growth factor receptors), in 25 percent of patients treated with the cyclin-dependent kinase 4/6 inhibitor <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F207103s000lbl.pdf%3Fet_cid%3D35396189%26et_rid%3D907466112%26linkid%3Dhttp%253a%252f%252fwww.accessdata.fda.gov%252fdrugsatfda_docs%252flabel%252f2015%252f207103s000lbl.pdf&amp;token=syQP9kPc9h1%2FHNoMJ1N50bWp%2FyPIHQT9Gx4%2Fqx0nPxBm3RUYM0K%2Fqqe09vJUJu8MmcwEh2ET3jSErD3vel78YESq2W69HS2OFGkZG8X0PxIjGel%2BsTmT5dNWkrcqdyvoYCKlYyt8ghNhz7crHvQRG1%2BCeLwTHK4MoKJbR%2FviJO33wtKSO5HfNvw8FnVj9Xu%2F&amp;TOPIC_ID=1152" target="_blank">palbociclib</a>, in 20 percent of patients treated with the poly (ADP-ribose) polymerase (PARP) inhibitor <a class="drug drug_general" data-topicid="112483" href="/d/drug information/112483.html" rel="external">niraparib</a>, and in 10 to 46 percent of patients treated with agents that target the epidermal growth factor receptor (EGFR), such as <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="119171" href="/d/drug information/119171.html" rel="external">dacomitinib</a>, and <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a>; most cases are mild to moderate [<a href="#rid11">11-13</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Higher rates of stomatitis (72 percent all grade, 9 percent grade 3 or worse) are reported with <a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a>, which blocks signaling from the EGFR1, (erbB1), EGFR2 (HER2/erbB2), and erbB4 [<a href="#rid14">14</a>], and with the oral fibroblast growth factor receptor inhibitors <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> (56 percent all grade, 9 percent grade 3 or worse), and <a class="drug drug_general" data-topicid="131754" href="/d/drug information/131754.html" rel="external">infigratinib</a> (56 percent all grade, 15 percent grade 3 or 4) [<a href="#rid15">15,16</a>]. Most cases with all of these agents are mild. (See  <a class="medical medical_review" href="/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Oral toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In addition, oral mucosal lesions (both typical ulcerations caused by loss of mucosal integrity and discrete aphthous-like ulcerations with an underlying inflammatory mechanism) have been seen in up to 73 percent of patients treated with the mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>; they are severe (grade 3 or worse,  (<a class="graphic graphic_table graphicRef60597" href="/d/graphic/60597.html" rel="external">table 2</a>)) in approximately 4 to 8 percent [<a href="#rid12">12,17-25</a>]. In a review, mTOR inhibitor-associated stomatitis was the most frequent adverse event overall associated with these drugs (73 percent), accounted for almost 30 percent of dose reductions, and was the most frequent dose-limiting toxicity (53 percent) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint inhibitors</strong> – Mucosal toxicities associated with the use of immune checkpoint inhibitors include periodontal disease and stomatitis, as well as oral lichen planus, xerostomia, and rarely, a Sjögren's disease-like condition affecting the salivary glands, and mucous membrane pemphigoid-like lesions [<a href="#rid26">26,27</a>]. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors", section on 'Mucosal toxicities'</a>.)</p><p></p><p class="headingAnchor" id="H3629564583"><span class="h3">Preexisting oral disease</span><span class="headingEndMark"> — </span>Oral disease that is present prior to treatment is thought to increase the risk of chemotherapy-induced mucositis. Within the general population, up to 75 percent have chronic periodontal disease [<a href="#rid28">28-30</a>]. (See  <a class="medical medical_review" href="/d/html/3417.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections"</a>.)</p><p>A number of dental conditions have been causally linked with an increased risk for stomatotoxicity, based upon empiric evidence and published data [<a href="#rid31">31,32</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Poor oral hygiene</p><p class="bulletIndent1"><span class="glyph">●</span>Caries and associated periapical pathology</p><p class="bulletIndent1"><span class="glyph">●</span>Periodontal disease</p><p></p><p class="headingAnchor" id="H1160348892"><span class="h3">Other factors</span><span class="headingEndMark"> — </span>Younger patients have a relatively greater risk of chemotherapy-induced stomatitis, perhaps related to a higher epithelial mitotic rate [<a href="#rid33">33</a>]. Other factors that may modulate the severity of stomatitis include nutritional status, the specific treatment protocol, the quality of oral care during treatment, pretreatment neutrophil counts, the use of hematopoietic growth factor support during therapy, and differences in the oral microbiome [<a href="#rid5">5,32,34,35</a>].</p><p>A role for genetic susceptibility (eg, inherited polymorphisms in drug-metabolizing enzymes and proinflammatory cytokines) is likely but not yet proven [<a href="#rid36">36-38</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Clinical manifestations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conventional cytotoxic agents</strong> – For conventional cytotoxic agents, direct stomatotoxic effects typically start at day 7 and peak by day 10 to 14.</p><p></p><p class="bulletIndent1">The initial clinical manifestation is soft tissue erythema of the buccal mucosa or soft palate with a burning sensation in the mouth. This stage may be followed by the development of solitary, elevated, white desquamative patches that are slightly painful. With further progression, epithelial sloughing results in multiple shallow ulcerations with a pseudomembranous appearance  (<a class="graphic graphic_picture graphicRef100762" href="/d/graphic/100762.html" rel="external">picture 1</a>), which coalesce to form large, painful ulcerations and cause dysphagia and reduced oral intake.</p><p></p><p class="bulletIndent1">The severity ranges from mild mouth soreness with a paucity of clinical findings to severe erosive mucositis that is accompanied by severe pain and an inability to eat or drink. Severe pseudomembranous or erosive mucositis can lead to secondary infection or sepsis (particularly in the presence of concomitant neutropenia), and necessitate the use of <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> and/or opiates. In addition, oral or gingival bleeding can occur if the patient becomes thrombocytopenic. Occasionally, pain may precede the mucosal changes. (See <a class="local">'Infectious complications'</a> below.)</p><p></p><p class="bulletIndent1">Mucositis is typically a self-limited phenomenon. Following conventional cytotoxic chemotherapy, which is typically administered episodically in cycles, the mucosal lesions spontaneously begin to resolve within several days and are usually completely healed within 10 to 14 days after onset, frequently improvement is concurrent with neutrophil recovery [<a href="#rid30">30</a>]. Severe (grade 3 or 4) symptoms may necessitate dose reduction during subsequent treatment cycles. However, only rarely is cessation of therapy required because of severe mucosal toxicity (eg, in a patient with dihydropyrimidine dehydrogenase deficiency who is receiving FU). (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Fluorouracil'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecularly-targeted agents</strong> – In general, the oral mucositis seen with molecularly targeted agents tends to be of a lesser severity than with conventional cytotoxic agents [<a href="#rid12">12,39</a>]. (See <a class="local">'Specific anticancer agents'</a> above.)</p><p></p><p class="bulletIndent1">The time to onset is typically earlier (two to three days after treatment initiation) with molecularly targeted agents, especially with mTOR inhibitors. With episodic administration (eg, <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>), mucositis is typically self-limited. However, for tyrosine kinase inhibitors that are dosed continuously on a daily basis, mucositis may be continuous, although it may lessen over time or with weeks off of therapy, depending on the specific agent.</p><p></p><p class="bulletIndent1">The clinical appearance is distinct from that associated with conventional cytotoxic agents. It is almost exclusively aphthous-like and well-defined  (<a class="graphic graphic_picture graphicRef134714" href="/d/graphic/134714.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef134499" href="/d/graphic/134499.html" rel="external">picture 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint inhibitors</strong> –The mucositis associated with immune checkpoint inhibitors has a variable presentation, but often with lichenoid features. Oral lichenoid reactions typically present with reticulate, white streaks (Wickham striae) or erosive lesions. While the mucositis is potentially severe, it is generally low-grade. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors", section on 'Mucosal toxicities'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Grading severity</span><span class="headingEndMark"> — </span>A variety of grading systems incorporating both subjective and objective criteria have been utilized to define the severity of mucositis. The most commonly used, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fctep.cancer.gov%2FprotocolDevelopment%2Felectronic_applications%2Fctc.htm&amp;token=L1PKi7ksomh1JqUfTKWNe61gdDEj7%2FEN0gFsM2jnisnZ9aDYBZ%2FnKF0Y6hAnywy9MOvaze9hPSMvHYdMdeBk6asiYcR9Y9yHOUcUYVkBUtI%3D&amp;TOPIC_ID=1152" target="_blank">National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)</a>, grades the severity of mucositis on a scale from 1 to 5, based upon the clinical findings and symptomatology; the most recent version is outlined in the table  (<a class="graphic graphic_table graphicRef60597" href="/d/graphic/60597.html" rel="external">table 2</a>).</p><p>The World Health Organization also has a grading scale, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 0 – No oral mucositis</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 1 – Erythema and soreness</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 2 – Ulcers; able to eat solid food</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 3 – Ulcers; but requires liquid diet (due to mucositis)</p><p class="bulletIndent1"><span class="glyph">●</span>Grade 4 – Ulcers; alimentation not possible due to mucositis</p><p></p><p>Another scale, the University of Nebraska Oral Assessment Score, has been used to evaluate the clinical course of mucositis in recipients of high-dose therapy and HCT [<a href="#rid40">40</a>]. It assigns a numeric grade to eight different aspects of the oral assessment (possible range of scores, 8 to 24). Patients with higher peak mucositis scores (≥18 versus &lt;18) had a significantly greater incidence of positive blood cultures (60 versus 30 percent) and a higher transplant-related mortality rate (24 versus 4 percent). (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Infectious complications</span><span class="headingEndMark"> — </span>An intact oral mucous membrane creates a physical barrier to pathogens and provides clearance of adhering microorganisms through the regular sloughing of surface epithelial cells [<a href="#rid4">4</a>]. Breakdown of the mucosal barrier predisposes to bacterial, fungal (especially Candida albicans), and viral superinfection, particularly as the hematologic nadir is reached after chemotherapy. The incidence and severity of infectious complications rise when the absolute neutrophil count (ANC) falls below 1000/microL.</p><p>An altered mucosal barrier can serve as the portal of entry for translocation of a variety of pathogens, including viruses, fungi, and bacteria into the bloodstream [<a href="#rid3">3,41,42</a>]. A relationship between mucositis and systemic bacteremia was shown in a study of 69 patients undergoing autologous HCT [<a href="#rid42">42</a>]. Patients who developed alpha hemolytic streptococcal bacteremia (n = 24) were significantly more likely to have ulcerative mucositis (62 versus 36 percent), and in turn, the presence of ulcerative mucositis increased the likelihood of developing bacteremia threefold.</p><p class="headingAnchor" id="H8"><span class="h4">Oral candidiasis</span><span class="headingEndMark"> — </span>As noted above, the most common superinfecting organism in patients with chemotherapy-induced mucositis is Candida albicans. Many of these patients are already at risk for superficial oral candidiasis because they are immunocompromised as a result of their advanced cancer.</p><p>Mucositis also increases the risk that a superficial infection will disseminate [<a href="#rid7">7,43</a>]. As an example, in one series of patients undergoing high-dose chemotherapy for acute leukemia, systemic fungemia occurred almost exclusively in those with prior oropharyngeal candidiasis [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a>.)</p><p>Superficial oropharyngeal candidiasis can be treated topically with <a class="drug drug_general" data-topicid="9287" href="/d/drug information/9287.html" rel="external">clotrimazole</a> troches or <a class="drug drug_general" data-topicid="9712" href="/d/drug information/9712.html" rel="external">nystatin</a> suspension. Systemic therapy with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is generally not needed unless the patient cannot tolerate topical therapy. Refractory infection may require oral or parenteral fluconazole, or parenteral amphotericin B. (See  <a class="medical medical_review" href="/d/html/2432.html" rel="external">"Oropharyngeal candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H9"><span class="h4">HSV reactivation</span><span class="headingEndMark"> — </span>Given the high risk of reactivation, antiviral prophylaxis is indicated for herpes simplex virus (HSV)-seropositive patients who are undergoing either induction chemotherapy for acute leukemia or receiving high-dose "conditioning" regimens followed by HCT.</p><p>In the absence of antiviral prophylaxis, the oral cavity can be affected by viral pathogens. The most common is reactivation of HSV type 1 infection, which occurs in 65 to 90 percent of seropositive patients receiving high-dose chemotherapy followed by HCT [<a href="#rid44">44</a>].</p><p>Infection with HSV should be considered in the differential diagnosis of any patient who presents with mucosal vesicles or unusually painful oral ulcerations after chemotherapy, particularly if candidiasis is not clinically evident. Compared with the oral lesions typically associated with mucositis, the erosions associated with HSV reactivation are more atypical, irregular, and shallow, with a high degree of symptoms, with lesions more likely to present on the keratinized (ie, gingiva, tongue dorsum, hard palate) as compared with nonkeratinized mucosa. A swab of one of the lesions can be sent for viral culture; HSV is usually isolated within 72 hours. (See  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"</a>.)</p><p>Particularly among patients who are HSV-1 seropositive with moderate to severe mucositis, empiric antiviral therapy (ie, parenteral or oral <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, or oral <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>) can be initiated while awaiting culture results [<a href="#rid44">44</a>]. In studies involving immunocompromised hosts with mucocutaneous HSV infection (but not limited to those undergoing chemotherapy), the administration of acyclovir (250 mg/m<sup>2</sup> intravenous [IV] every eight hours) for seven days produced significantly shorter periods of viral shedding, more rapid lesion healing, and decreased pain [<a href="#rid45">45,46</a>].</p><p>Antiviral treatment for HSV infection and prophylaxis for HCT recipients are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/8287.html" rel="external">"Treatment and prevention of herpes simplex virus type 1 in immunocompetent adolescents and adults"</a> and  <a class="medical medical_review" href="/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients", section on 'Antiviral prophylaxis or pre-emptive therapy'</a>.)</p><p class="headingAnchor" id="H3129347962"><span class="h2">Management</span></p><p class="headingAnchor" id="H10"><span class="h3">Prophylactic oral care</span><span class="headingEndMark"> — </span>For most patients we suggest prophylactic oral care during systemic anticancer treatment, including a comprehensive oral examination before treatment initiation. This recommendation is consistent with joint updated guidelines from the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) [<a href="#rid47">47,48</a>] and the European Society of Medical Oncology (ESMO) [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic oral care</strong> – A comprehensive oral examination before the initiation of cancer therapy is desirable for all patients if feasible [<a href="#rid31">31</a>]. A program of aggressive preventive oral care appears to diminish the incidence of all oral complications of chemotherapy, although the available data on the benefits for prevention of oral mucositis are limited [<a href="#rid50">50-54</a>]. As an example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A benefit for weekly prophylactic oral care (teeth surface cleaning, scaling, and tongue cleaning) was shown in a small randomized controlled trial conducted in 169 women with metastatic breast cancer treated with <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> [<a href="#rid54">54</a>]. Fewer patients who received prophylactic oral care had grade 2 or worse mucositis (34 versus 54 percent), and fewer had everolimus dose reduction because of a severe adverse effect (22 versus 32 percent), the most common of which was stomatitis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, all studies examining the prophylactic benefit of oral care protocols have major flaws, and a 2019 systematic review by the MASCC/ISOO concluded that no guideline was possible regarding the use of professional oral care to prevent oral mucositis in patients undergoing systemic anticancer therapy [<a href="#rid47">47</a>]. Nevertheless, an expert guideline panel also concluded that, despite the lack of data, dental evaluation and treatment prior to cancer therapy are desirable to reduce the patient's risk for local and systemic infections from odontogenic sources [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1">Pretherapy oral hygiene protocols should include scaling and root planing, caries treatment, and endodontic therapy, if needed. In cases of severe odontogenic pathology, tooth extraction should be considered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulpoperiapical disease</strong> – Periapical radiolucencies may represent pulpoperiapical dental infection, especially in the presence of caries. However, these radiographic lucencies can also be associated with other noninfectious conditions, such as postendodontic healing of a treated infection in which the bone does not fill back in or, rarely, leukemic infiltrates at dental root apices [<a href="#rid7">7</a>]. Thus, the incidental finding of an asymptomatic periapical radiolucency requires no specific prechemotherapy intervention [<a href="#rid55">55,56</a>]. Dental or endodontic therapy should be pursued only in patients with signs and/or symptoms that are consistent with acute periapical infection [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periodontal disease</strong> – Pretherapy dental treatment is often recommended to eliminate potential sources of odontogenic infection. However, few outcome-oriented trials have been conducted that support prechemotherapy treatment of chronic periodontal disease [<a href="#rid34">34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one trial, 166 patients were randomly assigned to limited or intensive oral hygiene care to prevent mucositis during high-dose therapy and HCT [<a href="#rid57">57</a>]. Patients receiving intensive oral care had statistically significant (though clinically unimpressive) benefits in the incidence (85 versus 93 percent) and duration (17 versus 19 days) of moderate or severe mucositis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The effectiveness of a preventive oral protocol was evaluated in a prospective, controlled study of 96 children (age 1 to 16 years) with acute lymphoblastic leukemia [<a href="#rid58">58</a>]. Compared with the control children who only received treatment for dental complications rather than prophylaxis, the children in the prophylactic group had improved oral hygiene and a decreased incidence of mucositis and oral candidiasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On the other hand, in a retrospective review of 58 patients undergoing allogeneic or autologous HCT for a variety of malignancies, there was no significant difference in the incidence of infection, mucositis, or post-transplant survival in the group who underwent intensive dental evaluation and treatment pretransplant (n = 36), compared with those who did not [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A prospective pilot trial was conducted at the University of Chicago in which 48 consecutive adults with hematologic or solid malignant neoplasms were assessed for periodontal health prior to chemotherapy, and no pretherapy dental treatment was given to patients with chronic dental disease [<a href="#rid60">60</a>]. Of the 21 who had severe chronic periodontal disease, only two developed acute periodontal infection following chemotherapy, both of whom were managed with antibiotic therapy. In neither case was there interference with chemotherapy or an adverse effect on oncologic outcomes. The authors concluded that patients with chronic dental pathology can safely proceed with chemotherapy without dental intervention as conversion of chronic dental disease to an acute state during chemotherapy occurs infrequently.</p><p></p><p class="bulletIndent1">If an intertherapy dental infection does arise, it can usually be managed effectively without interrupting therapy or adversely affecting oncologic treatment outcomes. An exception is patients undergoing allogeneic HCT where the additional use of immunosuppressive medications adds additional risks. All efforts should be made to correct any ongoing dental issues prior to proceeding with transplantation.</p><p></p><p class="bulletIndent1">Because chronic periodontal disease is associated with a substantial microbial burden within the periodontal pocket, it should be suspected as a focus of infection in febrile neutropenic patients [<a href="#rid7">7</a>]. Invasive manipulation of the soft tissues prior to chemotherapy appears to have no adverse effect on the subsequent development of fever or bacteremia, although instrumentation should be avoided during periods of neutropenia [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tooth extraction</strong> – Tooth extraction is commonly recommended prior to therapy for patients with severe periodontal disease, and for those with nonrestorable teeth, necrotic teeth, teeth with periapical infection in which endodontic therapy is not feasible, or partially erupted third molars [<a href="#rid7">7</a>]. Pretherapy tooth extractions can be safely performed without significant risk of postextraction complications [<a href="#rid62">62,63</a>]. However, recommended guidelines include performing extractions at least 10 days prior to chemotherapy, minimizing tissue trauma during the procedure, and obtaining primary closure of the wound without the use of hemostatic packing agents. Platelet transfusion should be considered prior to the procedure if the platelet count is less than 50,000/microL [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1">If tooth extraction is emergently needed in the setting of severe neutropenia (ANC less than 500 to 1000/microL), antibiotic prophylaxis that provides appropriate coverage for Gram-positive and anaerobic organisms (eg, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> 600 mg prior to the procedure, followed by a postextraction course of antibiotics) is adequate for most patients. Severely immunocompromised patients or those with extensive prior antibiotic exposure may benefit from broader-spectrum antibiotic coverage.</p><p></p><p class="bulletIndent1">Issues related to invasive dentoalveolar procedures in patients who are receiving therapy with antiresorptive agents (ie, bisphosphonates, <a class="drug drug_general" data-topicid="15575" href="/d/drug information/15575.html" rel="external">denosumab</a>) and angiogenesis inhibitors for advanced cancer are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/96863.html" rel="external">"Medication-related osteonecrosis of the jaw in patients with cancer", section on 'Dentoalveolar surgery'</a> and  <a class="medical medical_review" href="/d/html/96863.html" rel="external">"Medication-related osteonecrosis of the jaw in patients with cancer", section on 'Prevention'</a>.)</p><p></p><p class="headingAnchor" id="H2465454887"><span class="h3">Patients receiving chemotherapy</span><span class="headingEndMark"> — </span>A number of strategies have been employed to prevent or minimize chemotherapy-induced mucositis [<a href="#rid3">3</a>]. Although the quality of evidence derived from randomized trials is limited [<a href="#rid65">65</a>], updated evidence-based clinical practice guidelines developed by the MASCC/ISOO identified oral cryotherapy, <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a>, and photobiomodulation as beneficial in select clinical settings, as discussed below [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H684246481"><span class="h4">Preventive treatments that may be beneficial</span></p><p class="headingAnchor" id="H15"><span class="h5">Oral cryotherapy</span><span class="headingEndMark"> — </span>For patients receiving bolus FU-containing chemotherapy we recommend oral cryotherapy (ice chips swished around the mouth for 30 minutes). We also suggest the use of oral cryotherapy in patients receiving high-dose <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> chemotherapy regimens as preparation for autologous HCT. The use of oral cryotherapy in patients receiving other high-dose chemotherapy regimens as preparation for HCT is reasonable given the low toxicity and low cost; however, there is less evidence for benefit.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – Most patients achieve cooling of the oral mucosa through intraoral administration of ice chips during chemotherapy administration. This is a cost effective and proven beneficial treatment. Another alternative is use of the Cooral intraoral cooling system. However, this is a more complex and more expensive alternative that is not necessarily more effective or better tolerated than ice chips.</p><p></p><p class="bulletIndent1">The Cooral system is a fitted device that is shaped and dimensioned to cool the gums, cheeks, tongue, palate and base of the mouth by circulating chilled water continuously within a closed channel [<a href="#rid66">66</a>]. The Cooral system was directly compared with intraoral administration of ice chips in a phase III trial involving 172 patients beginning high dose chemotherapy prior to autologous HCT for multiple myeloma or lymphoma [<a href="#rid67">67</a>]. Each cooling method was started 30 minutes before the chemotherapy infusion, and continued for 30 minutes after completion. Oral mucositis was quantified by an oral mucositis assessment scale (OMAS; a composite score graded 0 to 3 for severity of ulceration, and 0 to 2 for erythema; total score range 0 to 5). Following treatment, oral mucositis of any grade developed in 44 percent of the entire cohort (76 of 172) and was much more frequent (81 versus 38 percent) and more severe (50 versus 14 percent) in those with lymphoma rather than myeloma. Within the entire study cohort, there was no significant difference between the two cooling methods in peak oral mucositis (OMAS 0.99 versus 1.24 for the cooling device and ice chips, respectively, p = 0.351). However, when the analysis was limited to the 26 lymphoma patients, use of the intraoral cooling device was associated with lower peak OMAS score (1.77 versus 3.08, p = 0.047). Secondary outcomes (tolerability, pain score) also favored the intraoral cooling device.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluorouracil</strong><strong>-containing regimens</strong> – Stomatitis is a major dose-limiting toxicity of FU when it is administered as a short-term bolus, particularly using a monthly, rather than weekly, schedule of administration (the so-called Mayo regimen). Mucositis is less of a problem in patients who receive infusional FU-containing regimens. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent1">Because FU has a short plasma half-life, it was postulated that oral cryotherapy around the time of drug administration might induce local vasoconstriction, thereby reducing exposure of the oral mucosa to FU and decreasing the incidence and/or severity of mucositis.</p><p></p><p class="bulletIndent1">Several controlled trials provide evidence for the benefit of oral cryotherapy in patients receiving bolus FU [<a href="#rid68">68-71</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A Cochrane review of five trials totaling 444 individuals undergoing treatment with FU concluded that oral cryotherapy probably reduces the severity of oral mucositis of any severity (relative risk [RR] 0.61, 95% CI 0.52-0.72) and the incidence of severe oral mucositis (RR 0.4, 95% CI 0.27-0.61). The number needed to treat to prevent severe oral mucositis in one additional person was six (95% CI 5-9) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2020 systemic review conducted by MASCC/ISOO, which included seven trials of chemotherapy using bolus FU, concluded that there was sufficient evidence to recommend this practice, but that no recommendation could be made as to benefit in the setting of continuous-infusion FU or other conventional-dose chemotherapy regimens given the paucity of data [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">The optimal duration of cryotherapy was addressed in another randomized trial of 178 patients receiving leucovorin-modulated bolus FU [<a href="#rid74">74</a>]. No additional benefit was seen with 60, as compared with 30, minutes of cryotherapy.</p><p></p><p class="bulletIndent1">Clinical practice guidelines from several groups recommend the use of oral cryotherapy (ice chips swished around the mouth for 30 minutes) in patients receiving bolus FU-containing regimens [<a href="#rid48">48,49,75</a>]. However, bolus FU regimens are not commonly used in the clinic because of their less favorable toxicity profile, as compared with infusional regimens. The benefit of cryotherapy in patients receiving infusional FU-containing regimens is unknown. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditioning regimens for autologous HCT</strong> – Although data are more limited, cryotherapy may also be effective in preventing severe oral mucositis in patients receiving high-dose <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> or other high-dose chemotherapy regimens as conditioning for autologous hematopoietic cell transplantation (HCT); most of the data are in patients undergoing high-dose melphalan [<a href="#rid76">76-80</a>], but there is likely to be benefit with other regimens as well [<a href="#rid81">81,82</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The Cochrane review cited above included five studies, totaling 270 patients [<a href="#rid72">72</a>]. The authors concluded that oral cryotherapy might reduce oral mucositis of any severity (RR 0.59, 95% CI 0.35-1.01), but there was uncertainty surrounding the effect estimates; the 95 percent CI ranged from two patients needed to treat to benefit one additional person, to 111 needed to treat in order to harm one additional patient [<a href="#rid72">72</a>]. On the other hand, severe oral mucositis was probably reduced (RR 0.38, 95% CI 0.20-0.72).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2020 systematic review of five trials conducted by MASCC/ISOO concluded that the data were sufficient to recommend cryotherapy for the prevention of oral mucositis in the setting of autologous HCT using high-dose <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1">Year 2020 clinical practice guidelines from the MASCC/ISOO recommend the use of oral cryotherapy for patients undergoing autologous HCT when high-dose <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> is used [<a href="#rid48">48</a>]; however, a guideline from ESMO is a "suggestion" rather than a "recommendation" [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1">The optimal cryotherapy regimen/schedule is unclear, but results seem to be better if the oral cavity is kept cool continuously. In a randomized trial of 160 individuals receiving <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>/<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> conditioning regimens prior to allogeneic HCT, continuous oral cryotherapy from the beginning of the conditioning regimen infusion until the end or continuous cryotherapy from the midpoint of the conditioning regimen infusion until the end both resulted in a lower incidence and severity of mucositis compared with twice-daily application for 15 minutes each during the period of conditioning [<a href="#rid81">81</a>].</p><p></p><p class="bulletIndent1">We suggest beginning oral cryotherapy 15 minutes prior to, and continuing through the entire duration of, the chemotherapy infusion.</p><p></p><p>The clinical presentation, prevention, and management of oral mucositis after HCT are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'</a>.)</p><p class="headingAnchor" id="H16"><span class="h5">Palifermin</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> to prevent oral mucositis in patients undergoing autologous HCT with a preparative regimen containing total-body radiation, an approach that is consistent with updated guidelines from MASCC/ISOO and other expert groups. While the use of palifermin to prevent oral mucositis in patients undergoing autologous HCT using any preparative regimen with a high risk of significant mucositis is reasonable, the modest benefit seen with this agent must be balanced against its expense, the lack of benefit in preventing irritation of the rest of the gastrointestinal (GI) tract, and the lack of efficacy in other settings, such as allogeneic HCT and induction therapy for acute leukemia. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation", section on 'Oral mucositis'</a>.)</p><p>For patients who develop severe (grade 3 or worse) mucositis during treatment with an FU- or doxorubicin-based chemotherapy regimen, we suggest dose reduction for subsequent chemotherapy cycles rather than prophylactic IV <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a>. While palifermin could be considered in this setting, the drug is expensive, may not be reimbursed for this off-label use, and there are no data demonstrating that outcomes are better as compared with dose reduction.</p><p><a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">Palifermin</a> is a recombinant keratinocyte growth factor that stimulates proliferation and differentiation of epithelial cells, including those of the GI tract [<a href="#rid83">83</a>]. The efficacy of prophylactic IV palifermin is supported by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>Benefit was initially shown in a double-blind, placebo-controlled multicenter trial in which 212 patients undergoing autologous HCT for hematologic malignancies (with a preparative regimen [fractionated total-body irradiation (TBI), <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>] known to be associated with a high incidence of mucositis) were randomly assigned to receive either <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> (60 mcg/kg per day) or placebo for three days before and three days following stem cell infusion [<a href="#rid84">84,85</a>]. Significantly fewer patients receiving palifermin had grade 3 or 4 mucositis (63 versus 98 percent with placebo), and the duration of mucositis was shorter (median six versus nine days). These benefits were associated with significantly less use of opioid analgesics and total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> support.</p><p></p><p class="bulletIndent1">Largely as a result of these data, <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> was approved by the US Food and Drug Administration (FDA) to decrease the incidence and severity of severe oral mucositis associated with hematologic malignancies in patients receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support (when the preparative regimen is expected to result in mucositis grade 3 or worse in most patients).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of five randomized trials conducted by the MASCC/ISOO expert group [<a href="#rid86">86</a>] concluded that <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> was effective in preventing oral mucositis in patients undergoing autologous HCT that included TBI [<a href="#rid85">85,87-89</a>], but one trial did not show benefit for patients undergoing autologous HCT without TBI [<a href="#rid90">90</a>].</p><p></p><p>Clinical practice guidelines, including those from MASCC/ISOO, ESMO, the American Society of Clinical Oncology (ASCO; from 2008), and the National Comprehensive Cancer Network (NCCN; from 2008) recommend the use of prophylactic <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> in patients with hematologic malignancies who are undergoing autologous HCT using preparative regimens that include TBI [<a href="#rid48">48,49,75,91</a>]. However, since radiation-based conditioning regimens have largely been replaced with chemotherapy-only-based regimens followed by autologous HCT, the use of palifermin is relatively low. (See  <a class="medical medical_review" href="/d/html/15803.html" rel="external">"Early complications of hematopoietic cell transplantation"</a>.)</p><p>Benefit of <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> for prevention of oral mucositis in other settings is less certain:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial in the setting of allogeneic HCT failed to show any benefit for prophylactic use of <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> (incidence of grade 3 or 4 oral mucositis 81 versus 73 percent with placebo) [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, a randomized placebo-controlled trial of <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> in 160 patients undergoing induction chemotherapy for acute myeloid leukemia with <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>, high-dose <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> found no significant difference in the rate of grade 3 or 4 oral mucositis (the primary endpoint) in the palifermin group (4 versus 10 percent), a finding that was attributed to the lower-than-expected rates of mucositis in the control group [<a href="#rid93">93</a>]. While there was a significantly lower rate of grade 3 and 4 GI adverse events (diarrhea, vomiting, oral mucositis) overall with palifermin, this was mainly due to a reduction in severe diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two of three randomized trials suggest benefits from <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> among patients receiving less intense chemotherapy regimens (including <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> plus high-dose <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> and FU-based chemotherapy for colorectal cancer) [<a href="#rid94">94-96</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Cochrane review of six trials of HCT (five autologous [one with unpublished data], one allogeneic [<a href="#rid84">84,87,90,92,97,98</a>]) and the four trials conducted in patients receiving chemotherapy alone for other indications [<a href="#rid93">93-96</a>] came to the following conclusions [<a href="#rid99">99</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There might be a reduction in the risk of moderate to severe oral mucositis in adults receiving HCT after conditioning therapy for hematologic cancers (RR 0.89, 95% CI 0.80-0.99, low-quality evidence). However, the level of benefit is uncertain because of multiple factors in this population, including whether or not TBI was used and whether the transplant was autologous or allogeneic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>It is likely that there is a reduction in the risk of moderate to severe oral mucositis in adults receiving chemotherapy alone for mixed solid and hematologic cancers (RR 0.56, 95% CI 0.45-0.70, moderate-quality evidence).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2020 systematic review by an expert panel of the MASCC/ISOO concluded that no guideline recommendation was possible regarding the benefit of <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> in individuals undergoing chemotherapy outside of the setting of HCT.</p><p></p><p class="headingAnchor" id="H17"><span class="h5">Photobiomodulation (low-level laser therapy)</span><span class="headingEndMark"> — </span>The use of photobiomodulation (low-level laser therapy) to prevent oral mucositis in patients undergoing HCT conditioned with high-dose chemotherapy, with or without TBI, may be helpful and is recommended in updated guidelines from the MASCC/ISOO. Specific protocols are endorsed by MASCC/ISOO  (<a class="graphic graphic_table graphicRef121959" href="/d/graphic/121959.html" rel="external">table 3</a>). However, in most parts of the world, photobiomodulation is rarely used in clinical practice. It requires expensive equipment and specialized operator training, is limited to centers capable of supporting the necessary technology and training, and the relative benefits of photobiomodulation versus <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> in patients undergoing autologous HCT have not been addressed in any trial.</p><p>Several controlled trials suggest that pretreatment with an intraoral helium-neon laser (He-Ne laser), a form of low-level laser irradiation, reduces the severity of mucositis in patients undergoing conditioning therapy for HCT [<a href="#rid100">100</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 30 patients undergoing HCT were randomly assigned to observation or He-Ne laser treatment to the entire oral mucosa prior to myeloablative chemotherapy [<a href="#rid101">101</a>]. Those who received laser treatment had significantly lower cumulative mucositis scores and required significantly less <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> for oral pain; however, there was no difference in the need for parenteral nutritional support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial of 20 patients undergoing HCT, one side of each patient's oral cavity was exposed to the He-Ne laser prior to high-dose chemotherapy, while the contralateral side was sham treated and served as the control [<a href="#rid102">102</a>]. The severity of oral mucositis and pain scores were significantly lower for the treated versus the untreated side of the mouth.</p><p></p><p>A similar degree of benefit has been reported from the application of a low-power diode laser, which is less expensive and easier to use than the He-Ne laser [<a href="#rid100">100,103-108</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 38 patients undergoing autologous or allogeneic HCT were randomly assigned to photobiomodulation or control [<a href="#rid103">103</a>]. A significantly higher number of patients undergoing photobiomodulation prior to treatment had oral mucositis that was no worse than grade 2 (95 versus 32 percent in the control group), and fewer developed large (9.1 to 18 cm<sup>2</sup>) areas of oral ulceration (5 versus 74 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second trial, 70 patients undergoing autologous or allogeneic HCT were randomly assigned to one of two different low-level lasers (650 nm visible red and 780 nm infrared) or placebo [<a href="#rid104">104</a>]. All active photobiomodulation patients received daily direct intraoral laser treatment to the lower labial mucosa, right and left buccal mucosa, lateral and ventral surfaces of the tongue, and floor of the mouth. Treatment with the 650 nm wavelength (but not the 780 nm wavelength) significantly reduced the severity of oral mucositis and pain scores. Photobiomodulation was well tolerated, and no adverse events were noted.</p><p></p><p>A systematic review of biomodulation for management of oral mucositis in cancer patients concluded that the level of evidence was strong to recommend low-level laser light therapy to prevent oral mucositis in patients undergoing HCT conditioned with high-dose chemotherapy with or without total-body radiotherapy [<a href="#rid100">100</a>]. No guideline was possible for patients undergoing chemotherapy in other settings.</p><p>Photobiomodulation has been recommended in consensus guidelines, including those by the MASCC/ISOO and ESMO, to reduce the incidence of oral mucositis in patients receiving a conditioning regimen before HCT [<a href="#rid48">48,49,100</a>]. Two specific protocols have been endorsed in this setting by the MASCC/ISOO  (<a class="graphic graphic_table graphicRef121959" href="/d/graphic/121959.html" rel="external">table 3</a>).</p><p>The clinical practice guidelines from the MASCC/ISOO also recommend photobiomodulation to prevent treatment-related mucositis in patients with head and neck cancer who are undergoing radiation therapy with or without chemotherapy. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Laser therapy (photobiomodulation)'</a>.)</p><p>Because this therapy requires expensive equipment and specialized operator training, it is limited to centers capable of supporting the necessary technology and training. The relative benefits of photobiomodulation versus <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> in patients undergoing high-dose therapy and HCT have not been addressed in any trial. Because of these limitations, photobiomodulation is rarely used in clinical practice.</p><p class="headingAnchor" id="H1073857994"><span class="h5">Treatments that are not recommended</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">Glutamine</a> – Glutamine is a precursor for nucleotide synthesis and an important fuel source for rapidly dividing cells, such as the lining epithelia of the GI tract. It is postulated to facilitate healing of the GI mucosa, following damage by either radiation therapy or chemotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Parenteral</strong> – Supplementation with <strong>parenteral</strong> <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> has been studied in the setting of HCT. There was no evidence of benefit in terms of mitigation of mucositis incidence or severity [<a href="#rid109">109</a>], and updated clinical practice guidelines from MASCC/ISOO recommend against the use of parenteral glutamine to prevent mucositis in patients undergoing HCT [<a href="#rid48">48</a>]. These trials are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Glutamine supplementation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral</strong> – There are conflicting data regarding the benefit of <strong>oral</strong> <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> supplements for prevention of mucositis:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Oral <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> failed to prevent FU-related mucositis in at least two trials of patients receiving standard-dose FU-based chemotherapy [<a href="#rid110">110,111</a>]. However, a trial in children suggested a possible benefit from oral glutamine [<a href="#rid112">112</a>]. One potential explanation for the conflicting results may be that the poor solubility of glutamine may limit bioavailability to the mucosal surface. At least some data support the view that local uptake by the mucosa (provided by swishing of the product in the mouth) may be essential [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>An oral suspension formulation of L-glutamine (Saforis) may provide greater bioavailability to the oral mucosa. In a phase III trial, 326 women with breast cancer scheduled to receive an anthracycline and cyclophosphamide-based regimen were randomly assigned to receive Saforis (2.5 g three times a day for 14 days) or placebo for the first cycle, crossing over to the alternate for cycle 2 of treatment [<a href="#rid114">114</a>]. The incidence of mucositis grade ≥2 was significantly reduced in the Saforis group during the first cycle (39 versus 50 percent with placebo), as was the incidence of severe mucositis (grade ≥3, 1 versus 7 percent,  (<a class="graphic graphic_table graphicRef60597" href="/d/graphic/60597.html" rel="external">table 2</a>)). Patients receiving Saforis in treatment cycle 1 had a lower-than-expected rate of oral mucositis when crossed over to placebo for treatment cycle 2, indicating a significant carryover effect.</p><p></p><p class="bulletIndent2">Independent confirmation of benefit is needed before routine use of prophylactic <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> suspension can be recommended in any setting. A systematic review of the literature on oral glutamine in 2019 considered the evidence in support of oral glutamine to be insufficient, at least for the setting of HCT and solid tumors other than head and neck cancer receiving chemoradiotherapy [<a href="#rid115">115</a>]. Updated 2020 guidelines for the prevention and treatment of oral mucositis from the MASCC/ISOO suggest the use of oral glutamine to prevent oral mucositis in those with head and neck cancer undergoing chemoradiotherapy, but makes no recommendation for other groups [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Management and prevention'</a>.)</p><p></p><p class="bulletIndent2">At present, there is no commercially available formulation of any oral <a class="drug drug_general" data-topicid="8747" href="/d/drug information/8747.html" rel="external">glutamine</a> suspension that is approved for use in preventing oral mucositis. Saforis has not been approved for marketing by the FDA or any other regulatory agency.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium phosphate rinse</strong> – Benefit for neutral supersaturated calcium phosphate rinse (Caphosol <a class="drug drug_general" data-topicid="8793" href="/d/drug information/8793.html" rel="external">artificial saliva</a>) was suggested in a double-blind, placebo-controlled trial in which 95 patients undergoing HCT were randomly assigned to calcium phosphate rinse plus a topical <a class="drug drug_general" data-topicid="8462" href="/d/drug information/8462.html" rel="external">fluoride</a> versus topical fluoride alone [<a href="#rid116">116</a>]. Patients using the calcium phosphate rinse had a significantly shorter duration of mucositis (3.7 versus 7 days), and less pain and <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> use. Unfortunately, these results were not confirmed in a later randomized trial conducted in 220 children undergoing allogeneic HCT for any indication [<a href="#rid117">117</a>] and in a third trial compared with cryotherapy alone [<a href="#rid118">118</a>]. A year 2019 systematic review from the MASCC/ISOO concluded that no guideline was possible on the utility of calcium phosphate oral rinses for either prevention or treatment of oral mucositis [<a href="#rid115">115</a>], and no recommendation was made in the updated 2020 MASCC/ISOO guidelines for management of mucositis secondary to cancer therapy [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other approaches</strong> – Several other pharmacologic approaches have either failed to show efficacy in controlled studies, or insufficient data are available to assess their benefit [<a href="#rid86">86,119</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a><strong> mouthwash</strong> – Allopurinol mouthwashes have been used in an attempt to inhibit the activation of FU to fluorodeoxyuridine monophosphate in mucosal cells. Early reports of benefit [<a href="#rid120">120,121</a>] were not confirmed in a randomized trial [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9823" href="/d/drug information/9823.html" rel="external">Propantheline</a> – An anticholinergic agent, propantheline has been used to decrease salivary flow and thereby reduce oral mucosal delivery of <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, a drug that is secreted into saliva. In a small, randomized, placebo-controlled trial (n = 12), propantheline was associated with a lower incidence and severity of mucositis [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2">A protective effect of propantheline-induced xerostomia was also suggested in a larger, but uncontrolled, study of 31 patients receiving high-dose <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (3000 mg/m<sup>2</sup>) as a component of the ICE regimen (high-dose <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and etoposide) prior to HCT [<a href="#rid123">123</a>]. Although mucositis developed in 29 (90 percent), it was severe in only three (10 percent). The authors inferred benefit based upon a comparison with a published series of 46 patients treated with the same ICE regimen followed by autologous HCT but without <a class="drug drug_general" data-topicid="9823" href="/d/drug information/9823.html" rel="external">propantheline</a>, in which mucositis developed in all patients and was severe in 78 percent [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent2">These data are insufficient to recommend the routine prophylactic use of <a class="drug drug_general" data-topicid="9823" href="/d/drug information/9823.html" rel="external">propantheline</a> in any clinical setting.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematopoietic colony-stimulating factors</strong> – The possibility that hematopoietic colony-stimulating factors (CSFs) may protect against the development of chemotherapy-induced mucositis was initially raised in a randomized trial that examined the use of prechemotherapy granulocyte CSF (G-CSF) to maintain chemotherapy dose intensity in patients with advanced bladder cancer [<a href="#rid125">125</a>]. Unexpectedly, G-CSF was associated with a significantly lower incidence (11 versus 44 percent) and severity of mucositis. Data from subsequent trials with mucositis as a specific endpoint have been mixed:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Benefit was confirmed in at least four controlled trials using either subcutaneous/IV G-CSF or granulocyte-macrophage CSF (GM-CSF) in a variety of clinical settings [<a href="#rid126">126-129</a>], but at least one trial was negative in the setting of HCT [<a href="#rid130">130</a>].</p><p></p><p class="bulletIndent3">However, a 2017 Cochrane review of interventions to prevent oral mucositis found no compelling evidence of benefit for either GM-CSF or G-CSF [<a href="#rid99">99</a>].This conclusion was also echoed in a 2020 systematic review by an expert panel from MASCC/ISOO [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Topical application of CSFs in a mouthwash formulation has been explored in at least three randomized trials, one of which showed benefit [<a href="#rid131">131</a>], and the others, no benefit [<a href="#rid132">132,133</a>]. The use of topical CSFs to prevent radiation-induced mucositis is addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/3408.html" rel="external">"Management and prevention of complications during initial treatment of head and neck cancer", section on 'Mucositis'</a>.)</p><p></p><p class="bulletIndent2">Updated MASCC/ISOO clinical practice guidelines specifically suggest not using CSFs (parenteral or topical) to prevent oral mucositis in patients undergoing HCT [<a href="#rid48">48</a>], and we agree with this position.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">Chlorhexidine</a> – The benefit of chlorhexidine mouth rinses remains uncertain. Three randomized trials assessing the effectiveness of chlorhexidine for mucositis prevention in patients receiving chemotherapy have yielded conflicting results [<a href="#rid70">70,134,135</a>]. Two trials, one in patients undergoing HCT [<a href="#rid134">134</a>] and the other in those receiving standard-dose bolus FU plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> [<a href="#rid70">70</a>], demonstrated a significant decrease in the incidence of mucositis with chlorhexidine mouthwash relative to placebo. The third trial, conducted in patients receiving a variety of mucositis-inducing regimens, did not demonstrate a benefit compared with sterile water mouthwashes [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent2">A 2019 systematic review from the MASCC/ISOO concluded that no recommendation was possible for use of <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> mouthwashes to prevent oral mucositis in any setting, given the conflicting data [<a href="#rid47">47</a>], although the 2020 updated guideline emphasized that this did not exclude other indications for chlorhexidine, such as prevention or treatment of oral infection [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – Randomized, placebo-controlled trials have failed to confirm a consistent prophylactic benefit for <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">sucralfate</a> [<a href="#rid136">136-140</a>], prostaglandins [<a href="#rid141">141,142</a>], chamomile mouthwash [<a href="#rid143">143</a>], systemic <a class="drug drug_general" data-topicid="9772" href="/d/drug information/9772.html" rel="external">pilocarpine</a>, systemic <a class="drug drug_general" data-topicid="9757" href="/d/drug information/9757.html" rel="external">pentoxifylline</a>, and antimicrobial lozenges [<a href="#rid144">144</a>] and mouthwashes derived from a variety of medicinal plants [<a href="#rid145">145</a>]. The available data on <a class="drug drug_general" data-topicid="8533" href="/d/drug information/8533.html" rel="external">amifostine</a> are conflicting [<a href="#rid146">146</a>]. None of these agents can be considered useful for the prevention of chemotherapy-associated mucositis [<a href="#rid48">48,147</a>].</p><p></p><p class="bulletIndent2">The trefoil factor family of proteins comprises a group of GI peptides that are involved in the protection of the mucous epithelium. Benefit from an oral spray containing recombinant intestinal trefoil factor was suggested in a randomized, double-blind, placebo-controlled phase II trial conducted in patients who developed moderate to severe oral mucositis during the first cycle of FU-based chemotherapy for advanced colorectal cancer [<a href="#rid148">148</a>]. Patients who received one of two doses of the recombinant protein had a significantly lower incidence of moderate to severe mucositis during the second chemotherapy cycle (9 to 12 versus 48 percent). Independent confirmation of these results is needed. A 2017 Cochrane review of interventions to prevent oral mucositis concluded that there was no compelling evidence of benefit from human intestinal trefoil factor [<a href="#rid99">99</a>].</p><p></p><p class="headingAnchor" id="H21"><span class="h4">Treatment of established mucositis</span><span class="headingEndMark"> — </span>Treatment of mucositis due to conventional cytotoxic chemotherapy is supportive and aimed at symptom control. It consists of a combination of oral care (including rinses with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and/or <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>), topical mucosal protectants, and either topical or systemic analgesia. With the exception of topical and systemic analgesia, the evidence supporting benefit for intervention is weak. Updated guidelines from the MASCC/ISOO specifically recommend against the use of <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">sucralfate</a> to treat oral mucositis in patients with a solid cancer receiving cytotoxic chemotherapy, and consider the evidence to be insufficient to prompt a recommendation for any other form of treatment [<a href="#rid48">48</a>]. We agree with this position.</p><p class="headingAnchor" id="H22"><span class="h5">Routine oral care</span><span class="headingEndMark"> — </span>For patients with established mucositis, routine mouth care, including removal of dentures, atraumatic cleansing, and oral rinses with a weak solution of salt and baking soda (one-half teaspoon of salt and one teaspoon of baking soda in a quart of water), should be performed every four hours. Although the data on <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or bicarbonate rinses for the prevention or treatment of oral mucositis are limited, the MASCC/ISOO expert panel recognized that these inert bland rinses that increase oral clearance may be helpful for maintaining oral hygiene and improving patient comfort [<a href="#rid48">48</a>].</p><p>The oral cavity should be rinsed and wiped after meals, and dentures cleaned and brushed often to remove plaque. A soft toothbrush or foam swab (Toothette) cleans teeth effectively but may be too harsh for patients with moderate to severe stomatitis.</p><p><a class="drug drug_general" data-topicid="113931" href="/d/drug information/113931.html" rel="external">Hydrogen peroxide</a> (diluted 1:1 with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or water) may be used for gentle debridement. Duration of use of hydrogen peroxide should be limited as chronic therapy may delay healing.</p><p>The diet should be limited to foods that do not require significant chewing; acidic, salty, or dry foods should be avoided.</p><p class="headingAnchor" id="H475882560"><span class="h5">Analgesia</span><span class="headingEndMark"> — </span>Both topical and systemic approaches have been used to manage pain associated with mucositis:</p><p class="bulletIndent1"><span class="glyph">●</span>Topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> solutions provide pain relief but require frequent administration. In one trial, topical viscous lidocaine (2 percent) was more effective than <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, a kaolin and pectin suspension, or placebo [<a href="#rid149">149</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> is frequently combined with cleansing and/or coating agents, a mixture that is often referred to as "miracle mouthwash." There is no fixed formulation, and these mixtures are compounded differently by individual pharmacies, most of which have no set formula [<a href="#rid150">150</a>]. Commonly, these mouthwashes consist of astringent/anticholinergic agents (eg, <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>), antacids and/or mucosal protective agents (eg, magnesium <a class="drug drug_general" data-topicid="8499" href="/d/drug information/8499.html" rel="external">aluminum hydroxide</a>), and a topical anesthetic (eg, lidocaine). One example consists of viscous lidocaine (50 mL of a 2 percent solution), sodium bicarbonate (100 mL of a 1 mEq/mL solution), and diphenhydramine (50 mL of a 12.5 mg/5 mL solution) in 500 mL normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> (resultant fluid volume 700 mL) with instructions to swish and expectorate 10 to 15 mL four to six times per day. Another type of "miracle mouthwash" consists of a mixture of equal parts of viscous lidocaine, diphenhydramine, and magnesium aluminum hydroxide (Maalox).</p><p></p><p class="bulletIndent1">A commercially available preparation that includes both <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> and <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> plus a variety of coating agents is First Mouthwash BLM (swish and expectorate 10 to 15 mL four to six times daily).</p><p></p><p class="bulletIndent1">Notably, a systematic review of the management of oral mucositis concluded that there was no evidence supporting the use of mixed-medication mouthwashes for treatment of chemotherapy- or radiation-induced mucositis [<a href="#rid151">151</a>]. Patients may have adverse effects related to the <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> and <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>. Year 2020 guidelines from the Mucositis Study Group of the MASCC/ISOO make no recommendations about the use of mixed-medication mouthwashes [<a href="#rid48">48</a>], while the American Academy of Nursing (AAN) Choosing Wisely statement (in conjunction with the Oncology Nursing Society [ONS]) explicitly recommends against their use [<a href="#rid152">152</a>]. Instead, frequent and consistent oral hygiene with a soft toothbrush and use of a homemade salt-and-soda mouth rinse (one teaspoonful each of salt and <a class="drug drug_general" data-topicid="9928" href="/d/drug information/9928.html" rel="external">sodium bicarbonate</a> in a liter of water) can be used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical application of <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> sulfate (0.2%, 2 mg/mL in water, 15 mL swish for two minutes and expectorate) may shorten the duration and intensity of mouth pain, even in the absence of significant systemic absorption. One study of 26 patients who had chemoradiotherapy for head and neck cancer, which compared a morphine mouthwash versus a mixture of equal parts of viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, and magnesium <a class="drug drug_general" data-topicid="8499" href="/d/drug information/8499.html" rel="external">aluminum hydroxide</a>, demonstrated statistically significantly shorter duration and lower pain intensity with the morphine mouthwash [<a href="#rid153">153</a>]. However, most commercially available oral preparations of morphine sulfate contain <a class="drug drug_general" data-topicid="8959" href="/d/drug information/8959.html" rel="external">glycerin</a>, ethanol, or both. These are not suitable for topical application because alcohol can directly injure the mucosa while glycerin can damage tissues because it is hygroscopic. There are no reliable data on topical morphine in other populations. The updated 2020 MASCC/ISOO guidelines suggested this approach be limited to those with head and neck cancer receiving chemoradiotherapy, but a specific recommendation could not be made for other groups [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Topical <a class="drug drug_general" data-topicid="9390" href="/d/drug information/9390.html" rel="external">doxepin</a> rinse (0.5%) can provide clinically significant pain relief in patients with mucosal damage from a variety of cancer treatments [<a href="#rid154">154</a>]. Although the year 2014 MASCC/ISOO guideline suggested in favor of doxepin mouthwash [<a href="#rid155">155</a>], in 2020, this was changed to "no guideline possible" [<a href="#rid48">48</a>] based on the results of an updated systematic review in 2019 [<a href="#rid147">147</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain may be severe enough to require systemic oral or parenteral opioids. <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">Morphine</a> is recommended as the opioid of first choice for patient-controlled analgesia [<a href="#rid156">156</a>]. The oral route is preferred if the patient can swallow. Another option that is suitable for patients who cannot swallow is transdermal <a class="drug drug_general" data-topicid="8441" href="/d/drug information/8441.html" rel="external">fentanyl</a>. (See  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a>.)</p><p></p><p class="bulletIndent1">Particularly for severe mucositis in the setting of HCT, patient-controlled analgesia using <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a> with appropriate lock-outs is recommended so that pain medications can be delivered in a timely manner in hospitalized patients, especially those undergoing HCT [<a href="#rid48">48,155</a>]. Typically, both a basal rate and intermittent bolus administrations of narcotics are required to achieve adequate analgesia.</p><p></p><p class="headingAnchor" id="H3069359990"><span class="h5">Treatments of uncertain benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal protective agents</strong> – A variety of mucosal-protective agents have been used to protect the mucosal surfaces of the oral cavity, including Gelclair, Orabase, Episil (a patented mixture of soy phospholipid [lecithin] and glyceryl dioleate that forms a bioadhesive barrier), topical kaolin/pectin, oral antacids, and propolis (a resinous substance that is used in many parts of the world as a mouthwash) [<a href="#rid145">145,157</a>]. There is little, if any, evidence from adequately powered randomized trials to support benefit from any of these preparations, and two 2020 systematic reviews from expert MASCC/ISOO panels concluded that no guideline was possible [<a href="#rid119">119,147</a>].</p><p></p><p class="bulletIndent1">As an example, Gelclair is a bioadherent <a class="drug drug_general" data-topicid="9507" href="/d/drug information/9507.html" rel="external">oral mucosal barrier gel</a> containing (according to the FDA label) <a class="drug drug_general" data-topicid="9818" href="/d/drug information/9818.html" rel="external">maltodextrin</a>, polyvinylpyrrolidone, and sodium hyaluronate (but no alcohol or anesthetic agent). It provides a physical adherent barrier over mucosal surfaces, thereby shielding oral lesions from the effect of food, liquids, and saliva [<a href="#rid158">158</a>]. A reduction in oral discomfort within five to seven hours of initial treatment was observed in an uncontrolled, open-label study of 30 hospice patients (only three of whom had chemotherapy-related mucositis) [<a href="#rid159">159</a>]. Benefit continued for more than three hours after each dose in most patients.</p><p></p><p class="bulletIndent1">The manufacturer recommends that the contents of each packet be mixed in one tablespoon of water, rinsed in the mouth for one minute, and expectorated three times daily at least one hour before eating or drinking [<a href="#rid160">160</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> – Two pilot studies suggest more rapid resolution of mucositis with topical vitamin E treatment [<a href="#rid161">161-163</a>]. In one randomized, double-blind, placebo-controlled trial, six of nine patients treated with vitamin E had complete resolution of lesions, compared with only one of nine receiving placebo. Larger confirmatory studies are needed before the topical application of vitamin E can be considered a standard approach.</p><p></p><p class="bulletIndent1">A 2019 systematic review concluded that no guideline was possible regarding the use of topical <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> for treatment of oral mucositis in any clinical setting [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other treatments</strong> – Efforts to limit mucositis progression by blocking the mechanism of chemotherapy-induced toxicity are ongoing, but so far, they have a relatively limited role. <a class="drug drug_general" data-topicid="9953" href="/d/drug information/9953.html" rel="external">Sucralfate</a> (topical, systemic) is not recommended for treatment of oral mucositis-associated patients with solid tumors treated with cytotoxic chemotherapy [<a href="#rid136">136,147,164</a>]. However, mucositis due to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> may respond to <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> mouthwash [<a href="#rid161">161,165</a>] or to the systemic administration of <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> or <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (folinic acid). (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="headingAnchor" id="H1975723616"><span class="h3">Patients receiving molecularly targeted agents</span><span class="headingEndMark"> — </span>The MASCC/ISOO guidelines for management of mucositis secondary to cancer therapy [<a href="#rid48">48</a>] were not intended to apply to individuals who develop mucositis while undergoing treatment with a molecularly targeted agent. These include orally active receptor tyrosine kinase inhibitors that target, among others, the epidermal growth factor and vascular endothelial growth factor receptors, and inhibitors of the mTOR. (See <a class="local">'Specific anticancer agents'</a> above.)</p><p>There are few trials that have explored any treatment, preventive or otherwise, in this setting, and the best approach is uncertain.</p><p class="headingAnchor" id="H3971144699"><span class="h4">Dexamethasone mouthwash</span><span class="headingEndMark"> — </span>Benefit for a preventive dexamethasone-containing mouthwash in patients treated with mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors was suggested in the multicenter phase II SWISH trial, in which 92 postmenopausal women with metastatic, hormone-receptor-positive, HER2-positive breast cancer prescribed <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> (10 mg daily) and <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a> (25 mg daily) all received a daily mouthwash containing <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, starting on the first day of the first cycle. Patients were told to swish 10 mL of alcohol-free dexamethasone (0.5 mg/5 mL oral solution) for two minutes and spit, four times daily for eight weeks, and not to eat for one hour after using the mouthwash. The incidence of grade 2 or worse stomatitis at week 8 (the primary endpoint) was 2.4 percent, which compares favorably with the rate seen in a historical control group, women with hormone-receptor-positive metastatic breast cancer treated with combined everolimus/exemestane in the phase III, randomized BOLERO-2 trial of exemestane with or without everolimus (33 percent) [<a href="#rid166">166</a>]. Overall, 90 percent of patients reported no need for dietary restriction because of stomatitis. Although hyperglycemia was the most common toxicity with the dexamethasone mouthwash, rates were not significantly higher than those seen in the BOLERO-2 trial without prophylactic dexamethasone. (See  <a class="medical medical_review" href="/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Alternative front-line options'</a>.)</p><p>Although these results (and others using alternative glucocorticoid-containing oral rinses [<a href="#rid167">167</a>]) are intriguing, the only way to definitively address the benefit of a prophylactic dexamethasone-containing mouthwash in patients receiving mTOR inhibitors is with a properly performed, randomized, placebo-controlled trial.</p><p>Case series further support benefit from local and systemic corticosteroid therapy to treat mTOR inhibitor-associated stomatitis [<a href="#rid168">168-170</a>].</p><p class="headingAnchor" id="H4180201287"><span class="h4">Guidelines from expert groups</span><span class="headingEndMark"> — </span>Consensus-based guidelines from ESMO [<a href="#rid49">49</a>] endorse expert opinion-based recommendations for prevention and treatment of stomatitis related to molecularly targeted agents from at least three groups [<a href="#rid168">168-170</a>], which are summarized as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral care protocols are suggested to prevent mucositis across all targeted therapy modalities. (See <a class="local">'Prophylactic oral care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should rinse their mouths with a bland nonalcoholic sodium bicarbonate-containing mouthwash four to six times a day to prevent stomatitis. The frequency can be increased up to hourly, if necessary, to treat stomatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sugarless chewing gum or candy, salivary substitutes, or sialogogues can be suggested to treat oral dryness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adequate pain management (eg, anesthetic mouthwashes such as viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> 2 percent, coating agents, or systemic analgesics) should be provided to treat pain from stomatitis. Alternative administration routes, such as transdermal or intranasal routes, may be considered if taking drugs by mouth is painful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For ulcers, topical high potency corticosteroids are suggested initially (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> mouth rinse 0.1 mg/mL in case several locations in the oral cavity are involved and/or it is difficult to reach the ulcerations; <a class="drug drug_general" data-topicid="9276" href="/d/drug information/9276.html" rel="external">clobetasol</a> gel or ointment [0.05%] in case of limited locations and easy-to-approach ulcers). If there is no ulcer resolution, referral to an oral expert for intralesional steroid injection could be considered. For highly symptomatic ulcers or recurrent ulcers, systemic glucocorticoid therapy can be considered as initial therapy to bring symptoms under control quickly (high dose pulse 30 to 60 mg or 1 mg/kg daily oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> for one week, followed by dose tapering over the second week).</p><p></p><p class="headingAnchor" id="H958768332"><span class="h3">Patients receiving immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>There are no widely accepted preventive strategies. <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">Dexamethasone</a> mouthwash is a first-line treatment for patients who develop mucositis while receiving immune checkpoint inhibitor immunotherapy. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128565.html" rel="external">"Cutaneous immune-related adverse events associated with immune checkpoint inhibitors", section on 'Mucosal toxicity'</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">XEROSTOMIA</span><span class="headingEndMark"> — </span>Although more commonly attributed to radiation therapy exposure, changes in salivary gland function can also be caused by chemotherapy (including <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>) [<a href="#rid7">7,171,172</a>]. Reduced salivary flow can also result from anticholinergic medications given for therapy-induced nausea or diarrhea (eg, for irinotecan-related early diarrhea) (see  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Irinotecan'</a>). Clinical presentation is variable, with some patients presenting with dry mucous membranes of varying severity, while others complain of excessive saliva with drooling as a result of dysphagia or odynophagia. The major symptoms associated with xerostomia are dry, uncomfortable mucosal tissues and thick, ropy saliva, which may impair speech and swallowing. Affected patients may also complain of dysgeusia [<a href="#rid7">7</a>].</p><p>Chemotherapy-related xerostomia is typically reversible, with spontaneous resolution after completion of chemotherapy [<a href="#rid7">7</a>]. Although it can compound other complications, such as mucositis, this self-limiting form of xerostomia has no significant long-term effects on oral health. Therapy is symptomatic (eg, rinsing with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or the use of commercially available saliva substitutes). Dry, cracked lips can be treated with petroleum lubricants. (See  <a class="medical medical_review" href="/d/html/14923.html" rel="external">"Treatment of dry mouth and other non-ocular sicca symptoms in Sjögren’s disease"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">GINGIVAL BLEEDING</span><span class="headingEndMark"> — </span>Chemotherapy-induced thrombocytopenia can result in spontaneous gingival bleeding, especially if the platelet count falls below 15,000/microL [<a href="#rid173">173</a>]. Poor oral hygiene or minor oral trauma (eg, from poor fitting dentures, over vigorous brushing of teeth) may worsen this condition due to local inflammation. If brushing creates unacceptable tissue trauma or is painful, plaque control can be achieved with regular use of <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> oral rinses [<a href="#rid31">31</a>].</p><p>Gingival bleeding is reported in patients treated with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody targeting the vascular endothelial growth factor, but is rare [<a href="#rid174">174,175</a>].</p><p>Gingival hemorrhage is usually not a serious or life-threatening complication [<a href="#rid7">7</a>]. If significant spontaneous bleeding occurs, gauze soaked in <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> or <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a> can be locally applied to obtain hemostasis. Alternatively, custom-fitted mouth guards can be fabricated to serve as a stent, with or without the application of hemostatic agents. Biting down on a popsicle may aid in resolving persistent oozing. Platelet transfusions are rarely required, and resolution occurs quickly as the platelet count begins to rise toward normal levels spontaneously.</p><p class="headingAnchor" id="H20051867"><span class="h1">ALTERATIONS IN TASTE AND SMELL</span><span class="headingEndMark"> — </span>Transient alterations in taste and smell are common in patients receiving chemotherapy and may lead to reduced appetite, low energy intake, and weight loss [<a href="#rid176">176-180</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In two series with prospective assessment of cancer patients undergoing chemotherapy for a variety of cancer types, taste alterations were reported by 70 and 67 percent, respectively [<a href="#rid176">176,177</a>]. In one of the reports, 49 percent reported olfactory changes during chemotherapy [<a href="#rid177">177</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another cohort of 87 patients receiving chemotherapy for breast cancer or a gynecologic malignancy, the significant decrease in olfactory and gustatory function during chemotherapy was restored almost completely to normal by three months postchemotherapy [<a href="#rid179">179</a>]. Olfactory function of older patients was affected more than younger patients.</p><p></p><p>The conventional cytotoxic agents that have been most associated with taste alterations include anthracyclines, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, platinum agents, taxanes, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>.</p><p>Taste alterations have also been reported in patients treated with molecularly targeted agents, with the most common being <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a>, <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="10344" href="/d/drug information/10344.html" rel="external">temsirolimus</a>, <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, <a class="drug drug_general" data-topicid="17142" href="/d/drug information/17142.html" rel="external">vismodegib</a>, <a class="drug drug_general" data-topicid="103072" href="/d/drug information/103072.html" rel="external">sonidegib</a>, <a class="drug drug_general" data-topicid="119754" href="/d/drug information/119754.html" rel="external">glasdegib</a>, <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>, <a class="drug drug_general" data-topicid="85639" href="/d/drug information/85639.html" rel="external">pertuzumab</a>, and <a class="drug drug_general" data-topicid="10093" href="/d/drug information/10093.html" rel="external">lapatinib</a> [<a href="#rid181">181-191</a>].</p><p>Chemotherapy and targeted therapeutics may affect taste by direct taste receptor stimulation due to secretion of the drug in saliva or via gingival crevice fluid (patients frequently describe a metallic or chemical taste when chemotherapy is delivered), or by altering the signal transduction pathways that mediate taste [<a href="#rid188">188</a>]. In some cases, taste changes may persist after drug clearance, presumably due to direct damage to the taste buds [<a href="#rid1">1,192</a>].</p><p>The diagnosis and treatment of disorders of taste and smell are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6846.html" rel="external">"Taste and olfactory disorders in adults: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H4014700822"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/142134.html" rel="external">"Society guideline links: Mucositis"</a>.)</p><p class="headingAnchor" id="H968953175"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/87048.html" rel="external">"Patient education: Mouth sores from cancer treatment (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of oral complications</strong> – Oral complications resulting from systemic anticancer therapy include mucositis, saliva changes, taste alterations, infection, and gingival bleeding. All of these complications can cause pain and/or impair nutrition. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucositis</strong> – The principal manifestation of oral toxicity in patients receiving cytotoxic chemotherapy or molecularly targeted agents is mucositis. Risks are highest with <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, bolus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) agents that block signaling through the epidermal growth factor receptor and the fibroblast growth factor receptor, and mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitors. (See <a class="local">'Etiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For all patients initiating systemic anticancer therapy we suggest prophylactic oral care, including a comprehensive oral examination before the initiation of treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prophylactic oral care'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients receiving bolus FU-containing cytotoxic chemotherapy we recommend oral cryotherapy (ice chips swished around the mouth for 30 minutes) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). For patients receiving high-dose <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">melphalan</a> as preparation for autologous hematopoietic cell transplantation (HCT), we also suggest oral cryotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The use of oral cryotherapy in patients receiving other high-dose chemotherapy regimens as preparation for HCT is reasonable; however, there is less evidence for benefit. (See <a class="local">'Oral cryotherapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients undergoing autologous HCT with a preparative regimen containing total-body irradiation (TBI) we suggest <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). While use of palifermin to prevent oral mucositis in patients receiving other high-risk preparative regimens is reasonable, the modest benefit seen with this agent much be balanced against its expense, the lack of benefit in preventing irritation of the rest of the gastrointestinal tract, and the lack of efficacy in other settings, such as allogeneic HCT and induction therapy for acute leukemia. (See <a class="local">'Palifermin'</a> above.)</p><p></p><p class="bulletIndent3">For patients who develop severe (≥grade 3) mucositis during treatment with an FU- or doxorubicin-based chemotherapy regimen, we suggest dose reduction for subsequent cycles rather than prophylactic IV <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Photobiomodulation (low-level laser therapy) may be helpful in patients undergoing HCT conditioned with high-dose chemotherapy, with or without TBI, specific protocols are endorsed by expert groups  (<a class="graphic graphic_table graphicRef121959" href="/d/graphic/121959.html" rel="external">table 3</a>). However, photobiomodulation requires expensive equipment and specialized operator training, is limited to centers capable of supporting the necessary technology and training, and the relative benefits versus <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> have not been addressed in any trial. (See <a class="local">'Photobiomodulation (low-level laser therapy)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Because of high reactivation rates, antiviral prophylaxis is indicated for herpes simplex virus (HSV)-seropositive patients who are undergoing either induction chemotherapy for acute leukemia or receiving high-dose "conditioning" regimens followed by HCT. (See <a class="local">'HSV reactivation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – Treatment is supportive and mainly aimed at symptom control:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients should remove and frequently clean dentures, perform atraumatic cleansing of the oral cavity, and use oral rinses with a weak solution of salt and baking soda (one-half teaspoon of salt and one teaspoon of baking soda in a quart of water) every four hours. Rinsing with <a class="drug drug_general" data-topicid="8793" href="/d/drug information/8793.html" rel="external">artificial saliva</a> may lessen the duration and severity of mucositis. A soft toothbrush or foam swab (Toothette) cleans teeth effectively but may be too harsh for patients with moderate to severe stomatitis. (See <a class="local">'Routine oral care'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Limit diet to foods that do not require significant chewing; avoid acidic, salty, or dry foods. Patients unable to swallow foods or liquids, may require parenteral fluid and/or nutritional support.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adequate analgesia can sometimes be provided topically (eg, viscous <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>), but many patients require systemic opioids. (See <a class="local">'Analgesia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The benefit of compounded mixtures (such as "miracle mouthwashes") that contain mucosal protective coating agents, often with topical anesthetics, is uncertain, and for most patients we suggest against their use (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Treatments of uncertain benefit'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients receiving molecularly targeted agents, our suggested approach includes prophylactic oral care protocols including mouth rinses with sodium bicarbonate-containing mouthwashes adequate analgesia, and steroids (topical, intralesional, or systemic) for patients who develop ulcers during therapy. (See <a class="local">'Patients receiving molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Xerostomia</strong> – Xerostomia is an uncommon complication of chemotherapy. Therapy is symptomatic (eg, rinsing with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or the use of commercially available saliva substitutes). Dry, cracked lips can be treated with petroleum lubricants. (See <a class="local">'Xerostomia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gingival bleeding</strong> – Gingival bleeding is most commonly caused by thrombocytopenia. If significant spontaneous bleeding occurs, gauze soaked in <a class="drug drug_general" data-topicid="10285" href="/d/drug information/10285.html" rel="external">topical thrombin</a> can be locally applied to obtain hemostasis. Bleeding usually resolves rapidly as platelet counts increase following the hematologic nadir. Platelet transfusions are rarely required. (See <a class="local">'Gingival bleeding'</a> above.)</p><p></p><p class="headingAnchor" id="H131798409"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jean-Francois Bedard, DMD, and Joseph A Toljanic, DDS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin 2012; 62:400.</a></li><li><a class="nounderline abstract_t">Larsen AK, Thomsen C, Sanden M, et al. Taste alterations and oral discomfort in patients receiving chemotherapy. Support Care Cancer 2021; 29:7431.</a></li><li><a class="nounderline abstract_t">Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277.</a></li><li><a class="nounderline abstract_t">Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995.</a></li><li><a class="nounderline abstract_t">Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer 2019; 27:4023.</a></li><li><a class="nounderline abstract_t">Wardill HR, Sonis ST, Blijlevens NMA, et al. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer 2020; 28:5059.</a></li><li class="breakAll">Peterson DE, Schubert MM. Oral toxicity. In: The Chemotherapy Source Book, 3rd ed, Perry MC (Ed), Williams and Wilkins, Baltimore 2001.</li><li><a class="nounderline abstract_t">Gouyette A, Deniel A, Pico JL, et al. Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. Eur J Cancer Clin Oncol 1987; 23:1627.</a></li><li><a class="nounderline abstract_t">Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979; 2:225.</a></li><li><a class="nounderline abstract_t">Ishii E, Yamada S, Higuchi S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989; 17:429.</a></li><li><a class="nounderline abstract_t">Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17:135.</a></li><li><a class="nounderline abstract_t">Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 2011; 47:441.</a></li><li><a class="nounderline abstract_t">Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18:1454.</a></li><li><a class="nounderline abstract_t">Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327.</a></li><li class="breakAll">United States Prescribing Information for erdafitinib available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf (Accessed on April 18, 2019).</li><li class="breakAll">United States Prescribing information for infigratinib available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf (Accessed on June 02, 2021).</li><li><a class="nounderline abstract_t">Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010; 116:210.</a></li><li><a class="nounderline abstract_t">Vathsala A. Outcomes for kidney transplants at the National University Health System: comparison with overseas transplants. Clin Transpl 2010; :149.</a></li><li><a class="nounderline abstract_t">De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology 2011; 223:4.</a></li><li><a class="nounderline abstract_t">Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 2012; 48:340.</a></li><li><a class="nounderline abstract_t">Martins F, de Oliveira MA, Wang Q, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013; 49:293.</a></li><li><a class="nounderline abstract_t">Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520.</a></li><li><a class="nounderline abstract_t">Shameem R, Lacouture M, Wu S. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest 2015; 33:70.</a></li><li><a class="nounderline abstract_t">Rugo HS, Hortobagyi GN, Yao J, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 2016; 27:519.</a></li><li><a class="nounderline abstract_t">Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428.</a></li><li><a class="nounderline abstract_t">Shazib MA, Woo SB, Sroussi H, et al. Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. Oral Dis 2020; 26:325.</a></li><li><a class="nounderline abstract_t">Jacob JS, Dutra BE, Garcia-Rodriguez V, et al. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. J Natl Compr Canc Netw 2021; 19:1415.</a></li><li><a class="nounderline abstract_t">Rosenberg SW. Oral care of chemotherapy patients. Dent Clin North Am 1990; 34:239.</a></li><li><a class="nounderline abstract_t">Peterson DE, D'Ambrosio JA. Diagnosis and management of acute and chronic oral complications of nonsurgical cancer therapies. Dent Clin North Am 1992; 36:945.</a></li><li><a class="nounderline abstract_t">Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park) 2003; 17:1767.</a></li><li><a class="nounderline abstract_t">Consensus statement: oral complications of cancer therapies. National Institutes of Health Consensus Development Panel. NCI Monogr 1990; :3.</a></li><li><a class="nounderline abstract_t">Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 2003; 39:91.</a></li><li><a class="nounderline abstract_t">Sonis ST, Sonis AL, Lieberman A. Oral complications in patients receiving treatment for malignancies other than of the head and neck. J Am Dent Assoc 1978; 97:468.</a></li><li><a class="nounderline abstract_t">Sonis ST, Woods PD, White BA. Oral complications of cancer therapies. Pretreatment oral assessment. NCI Monogr 1990; :29.</a></li><li><a class="nounderline abstract_t">Mougeot JC, Stevens CB, Morton DS, et al. Oral Microbiome and Cancer Therapy-Induced Oral Mucositis. J Natl Cancer Inst Monogr 2019; 2019.</a></li><li><a class="nounderline abstract_t">Hahn T, Zhelnova E, Sucheston L, et al. A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation. Biol Blood Marrow Transplant 2010; 16:801.</a></li><li><a class="nounderline abstract_t">Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol 2011; 99:356.</a></li><li><a class="nounderline abstract_t">Bogunia-Kubik K, Mazur G, Urbanowicz I, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet 2006; 33:21.</a></li><li><a class="nounderline abstract_t">Elting LS, Chang YC, Parelkar P, et al. Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 2013; 21:3243.</a></li><li><a class="nounderline abstract_t">Rapoport AP, Miller Watelet LF, Linder T, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17:2446.</a></li><li><a class="nounderline abstract_t">Weisman SJ, Scoopo FJ, Johnson GM, et al. Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections. J Clin Oncol 1990; 8:453.</a></li><li><a class="nounderline abstract_t">Ruescher TJ, Sodeifi A, Scrivani SJ, et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82:2275.</a></li><li><a class="nounderline abstract_t">DeGregorio MW, Lee WM, Ries CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982; 50:2780.</a></li><li><a class="nounderline abstract_t">Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 1990; :103.</a></li><li><a class="nounderline abstract_t">Meyers JD, Wade JC, Mitchell CD, et al. Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am J Med 1982; 73:229.</a></li><li><a class="nounderline abstract_t">Mitchell CD, Bean B, Gentry SR, et al. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981; 1:1389.</a></li><li><a class="nounderline abstract_t">Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2019; 27:3949.</a></li><li><a class="nounderline abstract_t">Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2020; 126:4423.</a></li><li><a class="nounderline abstract_t">Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2015; 26 Suppl 5:v139.</a></li><li><a class="nounderline abstract_t">Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol 1988; 65:19.</a></li><li><a class="nounderline abstract_t">Saito H, Watanabe Y, Sato K, et al. Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis. Support Care Cancer 2014; 22:2935.</a></li><li><a class="nounderline abstract_t">Djuric M, Hillier-Kolarov V, Belic A, Jankovic L. Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer 2006; 14:137.</a></li><li><a class="nounderline abstract_t">Yoneda S, Imai S, Hanada N, et al. Effects of oral care on development of oral mucositis and microorganisms in patients with esophageal cancer. Jpn J Infect Dis 2007; 60:23.</a></li><li><a class="nounderline abstract_t">Niikura N, Nakatukasa K, Amemiya T, et al. Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. Oncologist 2020; 25:e223.</a></li><li><a class="nounderline abstract_t">Stevenson-Moore P. Oral complications of cancer therapies. Essential aspects of a pretreatment oral examination. NCI Monogr 1990; :33.</a></li><li><a class="nounderline abstract_t">Peters E, Monopoli M, Woo SB, Sonis S. Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients. Oral Surg Oral Med Oral Pathol 1993; 76:45.</a></li><li><a class="nounderline abstract_t">Borowski B, Benhamou E, Pico JL, et al. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol 1994; 30B:93.</a></li><li><a class="nounderline abstract_t">Levy-Polack MP, Sebelli P, Polack NL. Incidence of oral complications and application of a preventive protocol in children with acute leukemia. Spec Care Dentist 1998; 18:189.</a></li><li><a class="nounderline abstract_t">Melkos AB, Massenkeil G, Arnold R, Reichart PA. Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome. Clin Oral Investig 2003; 7:113.</a></li><li><a class="nounderline abstract_t">Toljanic JA, Bedard JF, Larson RA, Fox JP. A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer 1999; 85:1843.</a></li><li><a class="nounderline abstract_t">Weikel DS, Peterson DE, Rubinstein LE, et al. Incidence of fever following invasive oral interventions in the myelosuppressed cancer patient. Cancer Nurs 1989; 12:265.</a></li><li><a class="nounderline abstract_t">Overholser CD, Peterson DE, Bergman SA, Williams LT. Dental extractions in patients with acute nonlymphocytic leukemia. J Oral Maxillofac Surg 1982; 40:296.</a></li><li><a class="nounderline abstract_t">Williford SK, Salisbury PL 3rd, Peacock JE Jr, et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989; 7:798.</a></li><li><a class="nounderline abstract_t">Fillmore WJ, Leavitt BD, Arce K. Dental extraction in the thrombocytopenic patient is safe and complications are easily managed. J Oral Maxillofac Surg 2013; 71:1647.</a></li><li><a class="nounderline abstract_t">Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2011; :CD000978.</a></li><li><a class="nounderline abstract_t">Walladbegi J, Gellerstedt M, Svanberg A, Jontell M. Innovative intraoral cooling device better tolerated and equally effective as ice cooling. Cancer Chemother Pharmacol 2017; 80:965.</a></li><li><a class="nounderline abstract_t">Walladbegi J, Henriksson R, Tavelin B, et al. Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. Bone Marrow Transplant 2022; 57:191.</a></li><li><a class="nounderline abstract_t">Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9:449.</a></li><li><a class="nounderline abstract_t">Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur J Cancer B Oral Oncol 1994; 30B:234.</a></li><li><a class="nounderline abstract_t">Sorensen JB, Skovsgaard T, Bork E, et al. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 2008; 112:1600.</a></li><li><a class="nounderline abstract_t">Katrancı N, Ovayolu N, Ovayolu O, Sevinc A. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial. Eur J Oncol Nurs 2012; 16:339.</a></li><li><a class="nounderline abstract_t">Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 2015; :CD011552.</a></li><li><a class="nounderline abstract_t">Correa MEP, Cheng KKF, Chiang K, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2020; 28:2449.</a></li><li><a class="nounderline abstract_t">Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72:2234.</a></li><li><a class="nounderline abstract_t">Bensinger W, Schubert M, Ang KK, et al. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008; 6 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer 2005; 13:266.</a></li><li><a class="nounderline abstract_t">Tartarone A, Matera R, Romano G, et al. Prevention of high-dose melphalan-induced mucositis by cryotherapy. Leuk Lymphoma 2005; 46:633.</a></li><li><a class="nounderline abstract_t">Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37:1031.</a></li><li><a class="nounderline abstract_t">Salvador P, Azusano C, Wang L, Howell D. A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. J Pain Symptom Manage 2012; 44:64.</a></li><li><a class="nounderline abstract_t">Gori E, Arpinati M, Bonifazi F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant 2007; 39:347.</a></li><li><a class="nounderline abstract_t">Lu Y, Zhu X, Ma Q, et al. Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study. Support Care Cancer 2020; 28:1747.</a></li><li><a class="nounderline abstract_t">Svanberg A, Birgegård G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. Support Care Cancer 2007; 15:1155.</a></li><li><a class="nounderline abstract_t">Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58:933.</a></li><li><a class="nounderline abstract_t">Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590.</a></li><li><a class="nounderline abstract_t">Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006; 24:5186.</a></li><li><a class="nounderline abstract_t">Logan RM, Al-Azri AR, Bossi P, et al. Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2020; 28:2485.</a></li><li><a class="nounderline abstract_t">Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108:3216.</a></li><li><a class="nounderline abstract_t">Lucchese A, Matarese G, Ghislanzoni LH, et al. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia. Leuk Lymphoma 2016; 57:820.</a></li><li><a class="nounderline abstract_t">Lucchese A, Matarese G, Manuelli M, et al. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial. Minerva Stomatol 2016; 65:43.</a></li><li><a class="nounderline abstract_t">Blijlevens N, de Château M, Krivan G, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. Bone Marrow Transplant 2013; 48:966.</a></li><li><a class="nounderline abstract_t">Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.</a></li><li><a class="nounderline abstract_t">Jagasia MH, Abonour R, Long GD, et al. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant 2012; 47:1350.</a></li><li><a class="nounderline abstract_t">Bradstock KF, Link E, Collins M, et al. A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia. Br J Haematol 2014; 167:618.</a></li><li><a class="nounderline abstract_t">Vadhan-Raj S, Trent J, Patel S, et al. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 2010; 153:358.</a></li><li><a class="nounderline abstract_t">Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21:1452.</a></li><li><a class="nounderline abstract_t">Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24:5194.</a></li><li><a class="nounderline abstract_t">Freytes CO, Ratanatharathorn V, Taylor C, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 2004; 10:8318.</a></li><li class="breakAll">Fink G, Ihorst G, Burbeck M, et al. Prospective randomized trial of palifermin (keratinocyte growth factor) versus best supportive care measures  for the decrease of oral mucositis in lymphoma patients receiving high-dose BEAM conditioning and autologous stem cell transplantation (ASCT). Onkologie. Jahrestagung der Deutschen, Osterreichischen und Schweizerischen Gesellschaften fur Hamatologie und Onkologie; 2011 Sept-Oct 30-04; Basel, Switzerland. Basel (Switzerland): S Karger AG, 2011; 302.</li><li><a class="nounderline abstract_t">Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. Cochrane Database Syst Rev 2017; 11:CD011990.</a></li><li><a class="nounderline abstract_t">Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2019; 27:3969.</a></li><li><a class="nounderline abstract_t">Cowen D, Tardieu C, Schubert M, et al. Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38:697.</a></li><li><a class="nounderline abstract_t">Barasch A, Peterson DE, Tanzer JM, et al. Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76:2550.</a></li><li><a class="nounderline abstract_t">Antunes HS, de Azevedo AM, da Silva Bouzas LF, et al. Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial. Blood 2007; 109:2250.</a></li><li><a class="nounderline abstract_t">Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007; 15:1145.</a></li><li><a class="nounderline abstract_t">Ferreira B, da Motta Silveira FM, de Orange FA. Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support Care Cancer 2016; 24:1035.</a></li><li><a class="nounderline abstract_t">Khouri VY, Stracieri AB, Rodrigues MC, et al. Use of therapeutic laser for prevention and treatment of oral mucositis. Braz Dent J 2009; 20:215.</a></li><li><a class="nounderline abstract_t">Silva GB, Mendonça EF, Bariani C, et al. The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial. Photomed Laser Surg 2011; 29:27.</a></li><li><a class="nounderline abstract_t">Silva LC, Sacono NT, Freire Mdo C, et al. The Impact of Low-Level Laser Therapy on Oral Mucositis and Quality of Life in Patients Undergoing Hematopoietic Stem Cell Transplantation Using the Oral Health Impact Profile and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation Questionnaires. Photomed Laser Surg 2015; 33:357.</a></li><li><a class="nounderline abstract_t">Uderzo C, Rebora P, Marrocco E, et al. Glutamine-enriched nutrition does not reduce mucosal morbidity or complications after stem-cell transplantation for childhood malignancies: a prospective randomized study. Transplantation 2011; 91:1321.</a></li><li><a class="nounderline abstract_t">Okuno SH, Woodhouse CO, Loprinzi CL, et al. Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy. Am J Clin Oncol 1999; 22:258.</a></li><li><a class="nounderline abstract_t">Jebb SA, Osborne RJ, Maughan TS, et al. 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994; 70:732.</a></li><li><a class="nounderline abstract_t">Aquino VM, Harvey AR, Garvin JH, et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2005; 36:611.</a></li><li><a class="nounderline abstract_t">Sonis ST. Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation? Nat Clin Pract Oncol 2006; 3:244.</a></li><li><a class="nounderline abstract_t">Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer 2007; 109:322.</a></li><li><a class="nounderline abstract_t">Yarom N, Hovan A, Bossi P, et al. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements. Support Care Cancer 2019; 27:3997.</a></li><li><a class="nounderline abstract_t">Papas AS, Clark RE, Martuscelli G, et al. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:705.</a></li><li><a class="nounderline abstract_t">Treister N, Nieder M, Baggott C, et al. Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br J Cancer 2017; 116:21.</a></li><li><a class="nounderline abstract_t">Svanberg A, Öhrn K, Birgegård G. Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur J Oncol Nurs 2015; 19:50.</a></li><li><a class="nounderline abstract_t">Yarom N, Hovan A, Bossi P, et al. Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents. Support Care Cancer 2020; 28:2457.</a></li><li><a class="nounderline abstract_t">Tsavaris N, Caragiauris P, Kosmidis P. Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes. Eur J Surg Oncol 1988; 14:405.</a></li><li><a class="nounderline abstract_t">Dozono H, Nakamura K, Motoya T, et al. [Prevention of stomatitis induced by anti-cancer drugs]. Gan To Kagaku Ryoho 1989; 16:3449.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. Cancer 1990; 65:1879.</a></li><li><a class="nounderline abstract_t">Ahmed T, Engelking C, Szalyga J, et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993; 12:131.</a></li><li><a class="nounderline abstract_t">Oblon DJ, Paul SR, Oblon MB, Malik S. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 1997; 20:961.</a></li><li><a class="nounderline abstract_t">Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318:1414.</a></li><li><a class="nounderline abstract_t">Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995; 13:2620.</a></li><li><a class="nounderline abstract_t">Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994; 5 Suppl 2:127.</a></li><li><a class="nounderline abstract_t">Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15:949.</a></li><li><a class="nounderline abstract_t">Crawford J, Tomita DK, Mazanet R, et al. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999; 5:187.</a></li><li><a class="nounderline abstract_t">Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11:307.</a></li><li><a class="nounderline abstract_t">Cartee L, Petros WP, Rosner GL, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995; 7:471.</a></li><li><a class="nounderline abstract_t">van der Lelie H, Thomas BL, van Oers RH, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. Ann Hematol 2001; 80:150.</a></li><li><a class="nounderline abstract_t">Dazzi C, Cariello A, Giovanis P, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Ann Oncol 2003; 14:559.</a></li><li><a class="nounderline abstract_t">Ferretti GA, Ash RC, Brown AT, et al. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988; 3:483.</a></li><li><a class="nounderline abstract_t">Dodd MJ, Larson PJ, Dibble SL, et al. Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 1996; 23:921.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:1235.</a></li><li><a class="nounderline abstract_t">Pfeiffer P, Madsen EL, Hansen O, May O. Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study. Acta Oncol 1990; 29:171.</a></li><li><a class="nounderline abstract_t">Nottage M, McLachlan SA, Brittain MA, et al. Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer 2003; 11:41.</a></li><li><a class="nounderline abstract_t">Ala S, Saeedi M, Janbabai G, et al. Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial. Nutr Cancer 2016; 68:456.</a></li><li><a class="nounderline abstract_t">Castagna L, Benhamou E, Pedraza E, et al. Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate. Ann Oncol 2001; 12:953.</a></li><li><a class="nounderline abstract_t">Dueñas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone Marrow Transplant 1996; 17:809.</a></li><li><a class="nounderline abstract_t">Labar B, Mrsić M, Pavletić Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993; 11:379.</a></li><li><a class="nounderline abstract_t">Fidler P, Loprinzi CL, O'Fallon JR, et al. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer 1996; 77:522.</a></li><li><a class="nounderline abstract_t">El-Sayed S, Nabid A, Shelley W, et al. Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 2002; 20:3956.</a></li><li><a class="nounderline abstract_t">Eubank PLC, Abreu LG, Violante IP, Volpato LER. Medicinal plants used for the treatment of mucositis induced by oncotherapy: a systematic review. Support Care Cancer 2021; 29:6981.</a></li><li><a class="nounderline abstract_t">Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21:357.</a></li><li><a class="nounderline abstract_t">Saunders DP, Rouleau T, Cheng K, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer 2020; 28:2473.</a></li><li><a class="nounderline abstract_t">Peterson DE, Barker NP, Akhmadullina LI, et al. Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. J Clin Oncol 2009; 27:4333.</a></li><li><a class="nounderline abstract_t">Carnel SB, Blakeslee DB, Oswald SG, Barnes M. Treatment of radiation- and chemotherapy-induced stomatitis. Otolaryngol Head Neck Surg 1990; 102:326.</a></li><li><a class="nounderline abstract_t">Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract 2005; 11:139.</a></li><li><a class="nounderline abstract_t">McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013; 21:3165.</a></li><li class="breakAll">Choosing Wisely Initiative. Available at: https://www.aannet.org/initiatives/choosing-wisely (Accessed on February 12, 2019).</li><li><a class="nounderline abstract_t">Cerchietti LC, Navigante AH, Bonomi MR, et al. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 2002; 95:2230.</a></li><li><a class="nounderline abstract_t">Epstein JB, Truelove EL, Oien H, et al. Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy. Oral Oncol 2001; 37:632.</a></li><li><a class="nounderline abstract_t">Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120:1453.</a></li><li><a class="nounderline abstract_t">Coda BA, O'Sullivan B, Donaldson G, et al. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997; 72:333.</a></li><li><a class="nounderline abstract_t">Kuo CC, Wang RH, Wang HH, Li CH. Meta-analysis of randomized controlled trials of the efficacy of propolis mouthwash in cancer therapy-induced oral mucositis. Support Care Cancer 2018; 26:4001.</a></li><li><a class="nounderline abstract_t">Hita-Iglesias P, Torres-Lagares D, Gutiérrez-Pérez JL. Evaluation of the clinical behaviour of a polyvinylpyrrolidone and sodium hyalonurate gel (Gelclair) in patients subjected to surgical treatment with CO2 laser. Int J Oral Maxillofac Surg 2006; 35:514.</a></li><li><a class="nounderline abstract_t">Innocenti M, Moscatelli G, Lopez S. Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study. J Pain Symptom Manage 2002; 24:456.</a></li><li class="breakAll">Gelclair drug information http://www.helsinn.com/Institutional.aspx?Root=212&amp;L2=232&amp;L3=274&amp;L4=270&amp;Lingua=EN (Accessed on April 09, 2012).</li><li><a class="nounderline abstract_t">Worthington HV, Clarkson JE, Eden OB. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2002; :CD001973.</a></li><li><a class="nounderline abstract_t">Wadleigh RG, Redman RS, Graham ML, et al. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med 1992; 92:481.</a></li><li><a class="nounderline abstract_t">Lopez I, Goudou C, Ribrag V, et al. [Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents]. Ann Med Interne (Paris) 1994; 145:405.</a></li><li><a class="nounderline abstract_t">Chiara S, Nobile MT, Vincenti M, et al. Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study. Anticancer Res 2001; 21:3707.</a></li><li><a class="nounderline abstract_t">Montecucco C, Caporali R, Rossi S, Porta C. Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis Rheum 1994; 37:777.</a></li><li><a class="nounderline abstract_t">Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol 2017; 18:654.</a></li><li><a class="nounderline abstract_t">Jones VE, McIntyre KJ, Paul D, et al. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. Oncologist 2019; 24:1153.</a></li><li><a class="nounderline abstract_t">Boers-Doets CB, Raber-Durlacher JE, Treister NS, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 2013; 9:1883.</a></li><li><a class="nounderline abstract_t">Pilotte AP, Hohos MB, Polson KM, et al. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. Clin J Oncol Nurs 2011; 15:E83.</a></li><li><a class="nounderline abstract_t">de Oliveira MA, Martins E Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47:998.</a></li><li><a class="nounderline abstract_t">Main BE, Calman KC, Ferguson MM, et al. The effect of cytotoxic therapy on saliva and oral flora. Oral Surg Oral Med Oral Pathol 1984; 58:545.</a></li><li><a class="nounderline abstract_t">Schum CA, Izutsu KT, Molbo DM, et al. Changes in salivary buffer capacity in patients undergoing cancer chemotherapy. J Oral Med 1979; 34:76.</a></li><li><a class="nounderline abstract_t">Peterson DE, D'Ambrosio JA. Nonsurgical management of head and neck cancer patients. Dent Clin North Am 1994; 38:425.</a></li><li><a class="nounderline abstract_t">Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26:399.</a></li><li><a class="nounderline abstract_t">Chura JC, Van Iseghem K, Downs LS Jr, et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007; 107:326.</a></li><li><a class="nounderline abstract_t">Zabernigg A, Gamper EM, Giesinger JM, et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 2010; 15:913.</a></li><li><a class="nounderline abstract_t">Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008; 16:275.</a></li><li><a class="nounderline abstract_t">Hong JH, Omur-Ozbek P, Stanek BT, et al. Taste and odor abnormalities in cancer patients. J Support Oncol 2009; 7:58.</a></li><li><a class="nounderline abstract_t">Steinbach S, Hummel T, Böhner C, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 2009; 27:1899.</a></li><li><a class="nounderline abstract_t">Amézaga J, Alfaro B, Ríos Y, et al. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. Support Care Cancer 2018; 26:4077.</a></li><li><a class="nounderline abstract_t">Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007; 13:2684.</a></li><li><a class="nounderline abstract_t">Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. Cancer 2008; 113:723.</a></li><li><a class="nounderline abstract_t">Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675.</a></li><li><a class="nounderline abstract_t">Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25:2191.</a></li><li><a class="nounderline abstract_t">Uemura H, Shinohara N, Yuasa T, et al. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40:194.</a></li><li><a class="nounderline abstract_t">Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978.</a></li><li><a class="nounderline abstract_t">Kimball KJ, Numnum TM, Kirby TO, et al. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol 2008; 111:95.</a></li><li><a class="nounderline abstract_t">van der Werf A, Rovithi M, Langius JAE, et al. Insight in taste alterations during treatment with protein kinase inhibitors. Eur J Cancer 2017; 86:125.</a></li><li><a class="nounderline abstract_t">Minami Y, Minami H, Miyamoto T, et al. Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies. Cancer Sci 2017; 108:1628.</a></li><li><a class="nounderline abstract_t">Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32:372.</a></li><li><a class="nounderline abstract_t">Malta CEN, de Lima Martins JO, Carlos ACAM, et al. Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study. Support Care Cancer 2022; 30:313.</a></li><li><a class="nounderline abstract_t">Bergdahl M, Bergdahl J. Perceived taste disturbance in adults: prevalence and association with oral and psychological factors and medication. Clin Oral Investig 2002; 6:145.</a></li></ol></div><div id="topicVersionRevision">Topic 1152 Version 74.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972543" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34080053" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Taste alterations and oral discomfort in patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15057287" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The pathobiology of mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15108222" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286231" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The pathogenesis of mucositis: updated perspectives and emerging targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592033" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592033" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2828072" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/313282" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Methotrexate-induced oral mucositis and salivary methotrexate concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2796859" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207567" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21514211" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Oral complications of targeted cancer therapies: a narrative literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958502" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816960" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19862817" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21696038" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outcomes for kidney transplants at the National University Health System: comparison with overseas transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21846963" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22206873" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312237" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22149876" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635371" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759276" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332142" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31642136" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34348238" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140102" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Oral care of chemotherapy patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1397442" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Diagnosis and management of acute and chronic oral complications of nonsurgical cancer therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723014" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188157" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Consensus statement: oral complications of cancer therapies. National Institutes of Health Consensus Development Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509961" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/279602" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Oral complications in patients receiving treatment for malignancies other than of the head and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2342592" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Oral complications of cancer therapies. Pretreatment oral assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425594" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral Microbiome and Cancer Therapy-Induced Oral Mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20074657" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A deletion polymorphism in glutathione-S-transferase mu (GSTM1) and/or theta (GSTT1) is associated with an increased risk of toxicity after autologous blood and marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704413" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426238" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23636648" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561308" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307989" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9610710" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6958353" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2160612" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7048914" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6113352" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286232" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786044" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142468" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2963246" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24854326" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16041502" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mucositis prevention by improved dental care in acute leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17314421" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of oral care on development of oral mucositis and microorganisms in patients with esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043762" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2342593" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Oral complications of cancer therapies. Essential aspects of a pretreatment oral examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8351120" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Assessment of the need for treatment of postendodontic asymptomatic periapical radiolucencies in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8032307" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10219183" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Incidence of oral complications and application of a preventive protocol in children with acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12768464" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Dental treatment prior to stem cell transplantation and its influence on the posttransplantation outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10223580" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2804961" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence of fever following invasive oral interventions in the myelosuppressed cancer patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6211528" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dental extractions in patients with acute nonlymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2523958" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The safety of dental extractions in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932116" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Dental extraction in the thrombocytopenic patient is safe and complications are easily managed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491378" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Interventions for preventing oral mucositis for patients with cancer receiving treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28975429" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Innovative intraoral cooling device better tolerated and equally effective as ice cooling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34728786" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1999715" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7950836" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18300265" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21911313" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26695736" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836937" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8374882" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289497" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : NCCN Task Force Report. prevention and management of mucositis in cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668755" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019498" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prevention of high-dose melphalan-induced mucositis by cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16633359" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672917" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277790" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31302767" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393189" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9500453" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15602019" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Palifermin for oral mucositis after intensive therapy for hematologic cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16391299" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080767" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16835378" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26428409" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26862696" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23241739" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018081" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22327131" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25142189" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855800" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697866" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075109" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623608" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623608" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29181845" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286228" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240635" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625084" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17053058" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Low-power laser in the prevention of induced oral mucositis in bone marrow transplantation patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393191" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26248655" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19784467" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Use of therapeutic laser for prevention and treatment of oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20969443" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The prevention of induced oral mucositis with low-level laser therapy in bone marrow transplantation patients: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154723" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The Impact of Low-Level Laser Therapy on Oral Mucositis and Quality of Life in Patients Undergoing Hematopoietic Stem Cell Transplantation Using the Oral Health Impact Profile and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation Questionnaires.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21499196" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Glutamine-enriched nutrition does not reduce mucosal morbidity or complications after stem-cell transplantation for childhood malignancies: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10362332" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Phase III controlled evaluation of glutamine for decreasing stomatitis in patients receiving fluorouracil (5-FU)-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7917930" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : 5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16086046" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16683001" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Can oral glutamine prevent mucositis in children undergoing hematopoietic stem-cell transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17154160" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31286229" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines-part 1: vitamins, minerals, and nutritional supplements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692611" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27875526" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224595" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32056010" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Systematic review of natural and miscellaneous agents, for the management of oral mucositis in cancer patients and clinical practice guidelines - part 2: honey, herbal compounds, saliva stimulants, probiotics, and miscellaneous agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3181443" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Reduction of oral toxicity of 5-fluorouracil by allopurinol mouthwashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679397" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : [Prevention of stomatitis induced by anti-cancer drugs].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2180557" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8401358" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Propantheline prevention of mucositis from etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9422475" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2452983" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595716" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7515645" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581096" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10850381" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7683552" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7578986" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320899" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649101" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3056555" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8829162" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060567" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1692228" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Effect of prophylactic sucralfate suspension on stomatitis induced by cancer chemotherapy. A randomized, double-blind cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527953" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27007594" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy of Sucralfate Mouth Wash in Prevention of 5-fluorouracil Induced Oral Mucositis: A Prospective, Randomized, Double-Blind, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11521801" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Prevention of mucositis in bone marrow transplantation: a double blind randomised controlled trial of sucralfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733702" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504271" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Prostaglandin E2 for prophylaxis of oral mucositis following BMT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630960" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351592" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33988743" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Medicinal plants used for the treatment of mucositis induced by oncotherapy: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23052919" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Systematic review of amifostine for the management of oral mucositis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32052137" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636011" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113258" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Treatment of radiation- and chemotherapy-induced stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595065" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Survey of topical oral solutions for the treatment of chemo-induced oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018908" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Systematic review of basic oral care for the management of oral mucositis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018908" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Systematic review of basic oral care for the management of oral mucositis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412178" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11590072" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24615748" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313274" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30022350" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Meta-analysis of randomized controlled trials of the efficacy of propolis mouthwash in cancer therapy-induced oral mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16497479" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Evaluation of the clinical behaviour of a polyvinylpyrrolidone and sodium hyalonurate gel (Gelclair) in patients subjected to surgical treatment with CO2 laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547044" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547044" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Efficacy of gelclair in reducing pain in palliative care patients with oral lesions: preliminary findings from an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869616" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Interventions for treating oral mucositis for patients with cancer receiving treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580295" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Vitamin E in the treatment of chemotherapy-induced mucositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864501" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : [Treatment of mucositis with vitamin E during administration of neutropenic antineoplastic agents].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11848548" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Sucralfate in the treatment of chemotherapy-induced stomatitis: a double-blind, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8185707" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Allopurinol mouthwashes in methotrexate-induced stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314691" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30833486" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24295418" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Mammalian target of rapamycin inhibitor-associated stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21951751" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890398" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Clinical presentation and management of mTOR inhibitor-associated stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6440071" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : The effect of cytotoxic therapy on saliva and oral flora.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/41889" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Changes in salivary buffer capacity in patients undergoing cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926196" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Nonsurgical management of head and neck cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202416" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17706754" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667968" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Taste alterations in cancer patients receiving chemotherapy: a neglected side effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17710445" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Self-reported taste and smell changes during cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19408458" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Taste and odor abnormalities in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289621" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29855774" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473200" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618737" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255327" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Phase II trial of sorafenib in metastatic thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538164" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897852" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761983" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692224" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28987769" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Insight in taste alterations during treatment with protein kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28556364" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846163" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34283319" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12271346" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Perceived taste disturbance in adults: prevalence and association with oral and psychological factors and medication.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
